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Zusammenfassung
Untersuchung strahlenbiologischer Effekte in der
intensita¨tsmodulierten Protonentherapie: Neue Strategien fu¨r
die inverse Bestrahlungsplanung
Zur Zeit werden Variationen der relativen biologischen Wirksamkeit (RBW) in der Be-
strahlungsplanung der intensita¨tsmodulierten Protonentherapie (IMPT) meist vernach-
la¨ssigt. Um mo¨gliche klinische Auswirkungen einer variablen RBW fu¨r gescannte Pro-
tonenstrahlen zu untersuchen, werden neue Strategien zur Beurteilung dieser strahlen-
biologischen Effekte und zur Integration der RBW in die inverse Bestrahlungsplanung
vorgestellt. Sie basieren auf einem schnellen Algorithmus zur dreidimensionalen Berech-
nung des dosis-gemittelten linearen Energietransfers (LET) als einem Maß der lokalen
Strahlenqualita¨t und auf einem einfachen pha¨nomenologischen Ansatz fu¨r die RBW als
Funktion der Dosis, des LET und des Gewebetyps. Es zeigte sich, dass der biologische
Effekt aufgrund unterschiedlicher LET-Verteilungen stark von der jeweils verwendeten
Scanning-Technik abhing. Neue Zielfunktionen zur Beru¨cksichtigung von LET und RBW
wurden in ein inverses Bestrahlungsplanungsprogramm integriert, welches nun eine gleich-
zeitige Vielfelder-Optimierung des biologischen Effekts in einer akzeptablen Zeit erlaubt.
An mehreren klinischen Beispielen wird demonstriert, wie mit diesen Methoden nachteilige
RBW-Effekte erkannt und durch die direkte Optimierung des Produkts von RBW und Do-
sis kompensiert werden ko¨nnen. Die vorgeschlagenen Strategien sind somit eine wertvolle
Hilfe, um die Qualita¨t von IMPT-Bestrahlungspla¨nen zu beurteilen und zu verbessern.
Abstract
Evaluation of Radiobiological Effects in Intensity Modulated
Proton Therapy: New Strategies for Inverse Treatment Planning
Currently, treatment planning for intensity modulated proton therapy (IMPT) usually
disregards variations of the relative biological effectiveness (RBE). To investigate the
potential clinical relevance of a variable RBE for beam scanning techniques, new strategies
for the evaluation of radiobiological effects and for the incorporation of the RBE into the
inverse planning process are presented. These strategies are based on a fast algorithm
for three-dimensional calculations of the dose averaged linear energy transfer (LET) as a
measure of the local radiation quality, and on a simple phenomenological approach for the
RBE as a function of dose, LET and tissue type. It was found that the biological effect
depended strongly on the type of scanning technique used, mainly due to differences in the
LET distributions. New objective functions that account for LET and RBE were integrated
into an inverse planning software, which now allows simultaneous multi-field optimization
of the biological effect in a reasonable time. With these methods, unfavourable RBE effects
can be identified and compensated for by direct optimization of the product of RBE and
dose, which is demonstrated for several clinical examples. The proposed strategies are
therefore valuable tools to evaluate and improve the quality of treatment plans in IMPT.
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Chapter 1
Introduction
Besides surgery and chemotherapy, radiation therapy is one of the three main options for
treating tumour patients. Over the last years, advances in research and technology led
to significant improvements in all fields of radiotherapy (for an overview see Webb 1993,
1997, 2001). While the majority of irradiations is done by high energy photons, another
promising approach is the treatment with proton beams, which enjoys rising interest and
importance with an increasing number of clinical proton therapy facilities worldwide. Due
to the different depth dose characteristic of charged particles compared to X-rays, superior
dose distributions in the patient and therefore higher tumour control and less side effects
can be anticipated for treatments with proton beams.
The most sophisticated technique in proton therapy is Intensity Modulated Proton Ther-
apy or IMPT (cf Lomax 1999), which involves narrow beam spots that are delivered to the
patient in a scanning pattern (cf Goitein and Chen 1983, Pedroni et al. 1995). The inten-
sity of the beam spots is modulated individually, and their relative weights are determined
by an optimization algorithm to obtain the best possible treatment plan. This process is
called inverse treatment planning, since it solves the problem of automatically finding the
best set of treatment parameters for a given (prescribed) dose distribution rather than the
other way round, which was the conventional approach in treatment planning systems.
Today, inverse planning for protons (cf Lomax 1999, Oelfke and Bortfeld 2001, Nill et al.
2004) is based on fast and reliable algorithms for dose calculation. However, the physical
dose is apparently not the only parameter one should look at in treatment planning for
protons, as there is experimental evidence that the biological effect caused by proton beams
does not depend on the physical dose alone (e.g. Belli et al. 1993, Wouters et al. 1996,
Skarsgard 1998, Paganetti et al. 2002), but also on the energy spectrum of the beam. In
other words: the same physical dose delivered by protons of different energy does not lead
1
1. Introduction
to the same biological results (e.g. in terms of cell survival). These radiobiological effects
need careful investigation, and their consideration in the optimization process might be
necessary to further improve the clinical results. The purpose of this work is therefore to
develop new strategies to evaluate radiobiological effects in IMPT, and to integrate them
into inverse treatment planning.
1.1 The relative biological effectiveness (RBE)
The biological effect of proton beams in comparison to a reference radiation is described by
the Relative Biological Effectiveness or RBE (cf Hall 2000, chap. 7, Wambersie and Menzel
1997, Wambersie 1999). It is defined as the ratio of the dose of the reference radiation
(Dref) and the respective proton dose (Dp) required to yield the same biological effect (e.g.
cell survival level S):
RBE(S) =
Dref(S)
Dp(S)
. (1.1)
Currently most clinical proton centres use a constant RBE of 1.1 relative to 60Co
(Gerweck and Kozin 1999, Paganetti et al. 2002), i.e. protons are assumed to be 10% more
effective than 60Co gamma-rays, although there is experimental evidence that the RBE is
not constant. In general, the RBE of protons depends on the dose or dose per fraction, the
tissue or cell type, the biological endpoint (e.g. cell survival or chromosome aberrations),
the reference radiation and the radiation quality, i.e. the local energy spectrum of the
protons (Skarsgard 1998, Hall 2000, Kraft 2000). The latter is often characterized by the
Linear Energy Transfer or LET, which can be understood as a measure of the density of
ionization events along the track of a proton. These dependencies of the RBE are most
obvious for in vitro experiments with cell cultures (e.g. Hall et al. 1978, Blomquist et al.
1993, Belli et al. 1993, Wouters et al. 1996, Tang et al. 1997). In most of these studies,
a clear increase of RBE with decreasing dose was found. Up to a certain LET maximum,
increasing LET also causes higher RBE values, which leads to variations of RBE with
depth in tissue, in particular at the end of the proton range. Beyond the LET maximum,
the RBE decreases again.
On the other hand, smaller RBE variations were found for in vivo systems (e.g. in animal
studies, cf Tepper et al. 1977, Gueulette et al. 2000, Ando et al. 2001). In particular,
the dose dependency of the RBE is less pronounced in vivo, while the increase of the
RBE at the end of the proton range can still be seen (e.g. Gueulette et al. 2001). Some
studies also evaluated the clinical experience with proton therapy (e.g. Debus et al. 1997,
Paganetti et al. 2002) and found no evidence that using a constant RBE of 1.1 significantly
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underestimated the real RBE, although this does neither prove that the RBE is constant,
nor that it is exactly 1.1 in all cases.
At the moment, the ability to determine or predict variable RBE values for clinical
applications is limited (Paganetti et al. 2002, Paganetti 2003). Therefore the use of a
constant RBE of 1.1 is continued in clinical practice of proton therapy, although the RBE
is in fact not constant. However, it is still under investigation whether the effects of a
variable RBE can be clinically significant, and there are doubts that a constant factor of
1.1 is sufficient for all cases. At least the increased effectiveness at the end of the range
of proton beams should certainly be accounted for in treatment planning (Paganetti et al.
2002). To clarify this situation, more radiobiological measurements are needed, especially
for in vivo systems and clinically relevant endpoints. Additionally, fast and robust tools
have to be developed that allow the integration of a variable RBE into the treatment
planning process in order to investigate the potential impact of RBE variations for different
irradiation conditions.
1.2 Objectives of this work
While new scanning techniques in intensity modulated proton therapy offer the possibility
to create highly conformal dose distributions for almost any desired target volume, there
are also some risks associated with them. It is therefore necessary to quantify and minimize
the impact of these potentially adverse effects, which include intra- and interfraction organ
motion, range uncertainties and the influence of a variable RBE. In this work, I will focus
on the last point and investigate radiobiological effects.
The aims of this thesis are therefore to study the potential clinical impact of a variable
RBE for various situations and compare these effects for different dose delivery techniques
(e.g. distal edge tracking and 3D modulation, see chapter 2). This question is particularly
interesting for IMPT since scanning techniques might show different biological properties
than the conventional delivery with passive beam scattering systems. Thus, it is highly
desirable to provide tools for a fast evaluation of RBE effects in treatment planning, i.e.
a method to identify situations where a constant RBE of 1.1 is not sufficient in clinical
practice. A first approach could be to take an existing model for a variable RBE (e.g.
track structure models, cf Paganetti and Goitein 2001) and apply it to the treatment
plan after the conventional optimization of the physical dose to obtain a three-dimensional
distribution of RBE× dose (sometimes also called “biological dose” or “effective dose”).
While this method could certainly be used to study the impact of a variable RBE and
to identify potentially dangerous situations, it does not offer an option to directly improve
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the biological outcome, since the optimization algorithm cannot take the RBE effects into
account. Therefore we would rather like to include the RBE into the optimization process
in order to achieve an optimized distribution of the biological effect or RBE× dose, because
only this approach can answer the question if and how disadvantageous RBE effects can
be compensated for in inverse treatment planning.
To integrate the RBE calculations into the optimization loop of inverse planning, a very
efficient RBE model is required to keep the optimization times reasonable. This means
that the track structure models (which need long computing times) are not suitable for
this purpose. Instead, a phenomenological model based on experimental data for the RBE
as a function of dose, LET and tissue type will be developed and employed in this work.
Despite being simple, it has to account for the most relevant properties of the RBE, in
particular the increase of RBE at the end of the proton range.
The assessment of RBE effects for complex IMPT treatment techniques therefore re-
quires three main components: i) a fast algorithm for three-dimensional LET calculations
to characterize and quantify the physical properties of the radiation field (cf Wilkens and
Oelfke 2003, 2004), ii) a simple and reliable method to compute the corresponding RBE
distributions and iii) the integration of these models into the inverse planning process.
The material in this thesis is organized as follows:
• In chapter 2, an introduction to proton therapy with particular emphasis on IMPT,
scanning techniques and the inverse planning process is given.
• Chapter 3 describes the algorithm for three-dimensional LET calculations, which —
in addition to the dose — will provide the physical input data for the following RBE
calculations.
• In chapter 4, the phenomenological model for the RBE as a function of dose, LET
and tissue type is presented and compared to experimental results.
• Chapter 5 then introduces new optimization strategies that integrate the RBE into
the optimization process, and the effects of a variable RBE are discussed for several
clinical examples.
• As an outlook, chapter 6 addresses the potential transfer of these strategies from
protons to heavier charged particles, e.g. for radiotherapy with carbon ions.
• Finally, a summary and the main conclusions are given in chapter 7.
4
Chapter 2
Intensity Modulated Proton Therapy
The therapeutical use of proton beams was proposed by Wilson in 1946, and the first
patients were irradiated in the 1950s and 1960s in the USA (Berkeley and Harvard), Sweden
(Uppsala) and the former Soviet Union (Dubna and Moscow). Since then, more than 36 000
tumour patients have been treated with protons all over the world (Sisterson 2004). The
number of proton facilities is increasing, and especially in the last few years a couple of new
hospital based proton accelerators started their operation in the USA and Japan, while
some more are under construction. Rather than the high energy physics laboratories,
where the first patients were treated, these new machines are dedicated only to medical
applications and can provide a patient friendly environment, higher patient throughput
and research facilities in the fields of oncology and medical physics.
In Germany only the Hahn-Meitner-Institute (HMI) in Berlin currently irradiates pa-
tients with protons, though their 68 MeV beam is only used for the treatment of ocular
tumours (Heese et al. 2001). However, several facilities with higher energies for deep seated
tumours are planned or under construction, in particular a centre for protons and heavier
ions at the University of Heidelberg and the Rinecker Proton Therapy Center (RPTC)
in Munich. Listings of all operating and proposed facilities can be found in the Particles
newsletter (Sisterson 2004).
Intensity modulated proton therapy (IMPT) is a special and relatively new technique of
proton therapy. One could argue that almost every kind of proton therapy involves some
degree of intensity modulation (e.g. the weighted superposition of pristine Bragg peaks
to yield a spread-out Bragg peak). However, following the argument of Lomax (1999),
IMPT is understood as a technique with several fields or beam ports that each create an
inhomogeneous dose distribution in the target; these fields are optimized in such a way
that their total dose distribution satisfies the clinical objectives, e.g. a homogeneous and
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conformal dose to the target volume while sparing neighbouring organs at risk. This is in
agreement with the current understanding of intensity modulated radiotherapy for photons
(IMRT, for an overview see Webb 2001). Compared to conventional techniques, intensity
modulation can yield better target coverage and improved sparing of normal tissues.
In this chapter, I will summarize the fundamentals of proton therapy in general, and in
particular of IMPT. Emphasis will be placed on those formulas and techniques that will
be needed in the subsequent chapters of this work. More detailed introductions into the
physics of proton therapy and into treatment planning for protons can be found in Bichsel
(1968), Webb (1993, chap. 4), Webb (1997, chap. 6) and Oelfke (2002). In section 2.1,
a brief review on the physical properties and therapeutical advantages of proton beams
is given. I will then describe current delivery techniques (section 2.2), with the focus on
scanning techniques that are employed in intensity modulated proton therapy. Finally, dose
calculation algorithms and optimization strategies for treatment planning will be addressed
in section 2.3.
2.1 Physical properties and therapeutical advantages
of proton beams
2.1.1 Stopping power, range and dose
In contrast to uncharged particles like photons, protons as charged particles have a dis-
tinctive range in matter. The depth dose curve shows a characteristic maximum, called
the Bragg peak (cf figure 2.1). The amount of energy that a proton looses per unit length
of its track is called the stopping power S(E), which can be obtained from Bethe’s formula
(see Johns and Cunningham 1983, ICRU 1993).
The range itself is defined as the position of the 80% dose behind the peak. The higher
the initial velocity or the kinetic energy of the protons, the greater is the range. In the
continuous slowing down approximation (CSDA), the range R for protons of energy E can
be calculated easily from the energy dependent stopping powers S(E) by
R(E) =
∫ 0
E
1
S(E ′)
dE ′. (2.1)
This range-energy relationship can be parameterized by a simple power law, which was
already given by Wilson (1946):
R = αEp. (2.2)
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Figure 2.1: Dose (——), fluence (· · · · · ·) and dose averaged LET (– – –, right ordinate)
along the central axis for a 160 MeV proton beam. A similar figure was already given by
Larsson (1961).
Using the stopping powers given in ICRU report 49 (1993), Bortfeld (1997) gave as a best
fit α = 0.0022 cm MeV−p and p = 1.77. The dose D at a specific point x (i.e. the absorbed
energy per unit mass) can be obtained by
D(x) =
1
ρ
∫ ∞
0
S(E)φE(x)dE, (2.3)
where ρ is the density of the material and φE(x) the fluence spectrum with respect to en-
ergy. Strictly speaking, this is cema (converted energy per unit mass) rather than absorbed
dose (Kellerer et al. 1992, ICRU 1998), which can be used as a good approximation of the
dose.
The stopping power quantifies the density of ionization events along the proton track,
and is usually given in units of keV/µm. It is strongly connected to the term “linear energy
transfer” (LET), which will be discussed in more detail in chapter 3. In figure 2.1 the dose
averaged LET as a local mean of the stopping power is also shown. The LET is low in the
entrance region, and rises first slowly and then very steeply at or behind the Bragg peak.
The characteristic depth dose curve with the Bragg peak (figure 2.1) illustrates the
therapeutical advantages of protons: the dose is low in the entrance region (where the
beam passes through normal tissue to reach the tumour), and the high dose region of the
Bragg peak can be conveniently placed in the target volume. Behind the peak, the steep
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dose falloff leads to an almost zero exit dose. The width of the Bragg peak is given by the
range straggling of the protons and by the initial width of the energy spectrum. Analytical
expressions for the depth dose curve have been developed by Bortfeld and Schlegel (1996)
and Bortfeld (1997).
The lateral dose falloff (“penumbra”) of a proton beam can be very sharp in the entrance
region, but it becomes broader with increasing depth in the tissue due to multiple Coulomb
scattering (Gottschalk et al. 1993). The lateral penumbra is therefore roughly the same as
for mega-voltage photon beams from linear accelerators. To gain a therapeutical advantage
in comparison to photons in the penumbra region, one would have to go to heavier charged
particles like helium or carbon ions, which show less lateral scattering in tissue.
2.1.2 Coulomb and nuclear interactions
The stopping power S(E) only accounts for Coulomb interactions. While those are cer-
tainly the majority, some protons also undergo nonelastic nuclear interactions. The latter
lead to the production of secondary particles (mainly protons, neutrons and alpha particles,
Paganetti 2002) and a reduction of the primary proton fluence with depth (cf figure 2.1
and Lee et al. 1993, Bortfeld 1997). While the dose due to secondary neutrons is very
low (Agosteo et al. 1998, Schneider et al. 2002), secondary protons and alpha particles can
contribute considerably to the dose, especially in the entrance region (Paganetti 2002).
A useful application of nuclear interactions are the positron emission tomography (PET)
measurements of β+ activity produced by protons interacting with light elements like car-
bon, nitrogen and oxygen (e.g. Oelfke et al. 1996, Parodi et al. 2002), which can in principle
be used to monitor the dose delivery process.
2.2 Delivery techniques for proton beams
2.2.1 Spread-out Bragg peaks
One single Bragg peak alone is in most cases not suitable for tumour treatments, simply
because the spatial dimensions of the high dose region are too small. To irradiate larger
targets, one has to superimpose several pristine peaks in a suitable way to obtain a ho-
mogeneous dose distributions in the planning target volume (PTV, cf ICRU 1999). The
classical way to accomplish this for a single beam direction are the so-called spread-out
Bragg peaks (SOBPs). Here several pristine peaks from the same incident beam angle are
modulated in energy, i.e. their range in the tissue is shifted individually. By using appro-
8
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Figure 2.2: Dose distribution in a spread-out Bragg peak (SOBP, thick line) with a
modulation width of 9 cm. In this example, the SOBP is the sum of eight constituent
pristine peaks with different positions and intensities (thin lines).
priate weights for every peak, a homogeneous high dose region can be achieved (figure 2.2).
The weights are usually obtained by an optimization algorithm (e.g. Gardey et al. 1999),
so that the range and the modulation width (usually the distance between the proximal
and distal 90% isodose) match the desired values.
In practice, SOBPs are mostly generated by rotating modulator wheels in the beam
line, although in principle it could be done with active energy variation as well. Upstream
of the modulator wheel, the beam is spread-out laterally, e.g. by a double scattering system
(Koehler et al. 1977). Before the beam enters the patient, the field can be shaped to the
lateral dimensions of the PTV by a brass collimator, and to the distal PTV edge by an
acrylic compensator, as it is for example routinely done in the Northeast Proton Therapy
Center (NPTC) in Boston (cf Bussie`re and Adams 2003).
This technique of SOBPs in conjunction with passive field shaping gives a homogeneous
dose in the PTV for a single beam direction, and can of course be applied to several
successive beam ports with different incident beam angles. However, this technique does
not fully exploit all possible degrees of freedom, and intensity modulated proton therapy
can be expected to yield superior dose distributions. The scanning techniques employed in
IMPT will be discussed in the following section.
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DET 3D modulation
Figure 2.3: Illustration of two spot scanning techniques for one of potentially many beam
directions: the distal edge tracking technique (left) places the beam spots at the distal edge
of the PTV (solid line) only, while beam spots are distributed all over the PTV for the 3D
modulation technique (right).
2.2.2 Scanning techniques
Lomax (1999) described four methods of intensity modulation for proton therapy. Based
on the degrees of freedom for the modulation, they were named two-dimensional (2D),
2.5D and 3D modulation, while the fourth method was already called distal edge tracking
(Deasy et al. 1997). The 2D and 2.5D techniques both work with narrow SOBPs, which are
scanned across the field while their intensity is modulated in the two lateral dimensions.
This can be done either using SOBPs of fixed extent (2D modulation), or by simultaneously
varying the modulation width of the SOBP in order to match the respective dimensions of
the planning target volume (2.5D modulation). For the two other techniques (DET and
3D modulation), narrow beam spots consisting of a single Bragg peak rather than SOBPs
are placed in the PTV, and their individual weights are optimized to achieve the desired
dose distribution.
For the purpose of this work, the latter approaches (DET and 3D modulation) seem to
be more interesting, as we do not only want to calculate three-dimensional distributions
of the relative biological effectiveness or RBE (which would be useful for all techniques),
but we rather want to include the RBE in the optimization loop to obtain the optimal
treatment plan in terms of the biological effect instead of the physical dose. This means
that the physical dose in the PTV will not necessarily be homogeneous, which renders
pre-defined SOBPs not very useful in this context. Only by optimizing the weights of all
Bragg peaks individually, one can fully exploit all possible degrees of freedom. Therefore,
I will concentrate in the following on the DET and 3D modulation techniques and will
describe only them in more detail.
10
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DET 3D modulation
integral dose ©+ ©-
optimization effort ©+ ©-
delivery effort ©+ ©-
delivery uncertainties ©- ©+
required number of beam ports ©- ©+
RBE effects ©- ? ©+ ?
Table 2.1: Summary of advantages and disadvantages of the DET and 3D modulation
techniques. While DET is superior in terms of integral dose and the effort for optimization
and delivery, it causes higher uncertainties in the delivery, can require more beam ports and
might show unfavourable biological effects. The latter will be investigated in more detail in
chapter 5.
The distal edge tracking technique was proposed by Deasy et al. (1997). For every
beam port, it uses single Bragg peaks that are placed only at the distal edge of the planning
target volume. For one beam direction, this is illustrated in figure 2.3. The modulation
is achieved by assigning individual weights to every beam spot. For a sufficient number
of beam angles, this technique can yield a homogeneous dose in the PTV. The ratio of
“energy deposited inside the target” and “energy deposited outside the target” can be
maximized for the DET technique (Deasy et al. 1997), which leads to better sparing of the
normal tissue surrounding the PTV and a reduced integral dose. This was also confirmed
in theoretical studies by Oelfke and Bortfeld (2000) for centrally located targets in rotation
therapy, especially for small target volumes.
On the other hand, the 3D modulation technique (sometimes also called 3D scanning)
employs much more beam spots. They are placed all over the PTV, and their weights
are varied independently (figure 2.3). The greater number of beam spots makes the whole
technique more complex and increases the effort required in computing and optimization
as well as for the delivery (Nill 2001). However, potential errors in the delivery process are
reduced compared to DET, since 3D modulation is less sensitive to organ movements or
to range uncertainties, which can for example be caused by errors in the calibration of the
X-ray computed tomography (CT) scanner used. The 3D modulation has more degrees of
freedom than DET and is therefore the most flexible technique. Especially when only a
small number of beam ports is used, the 3D modulation becomes superior to DET, since
it can achieve homogeneous dose distributions even for one single field (Lomax 1999).
Table 2.1 summarizes the advantages and disadvantages of the two techniques. One of
the aims of this work is to answer the interesting question about the potential effects of a
11
2. Intensity Modulated Proton Therapy
variable RBE in the two cases. Elevated RBE values can be expected at the distal edge of
every single beam spot (e.g. Paganetti and Schmitz 1996, Paganetti et al. 2002). For DET,
this may lead to higher RBE values at the border of the PTV than in its centre, while a
more homogeneous RBE distribution is expected for 3D modulation (Nill 2001, p 70). This
effect will be investigated in detail in chapter 5, and we will see whether such unfavourable
effects can be compensated for by appropriate modifications in the optimization process.
For the actual delivery of narrow proton beams in a scanning pattern, several technical
realizations have been developed over the last years. High energy proton beams are usually
produced in cyclotrons or synchrotrons, and a beam line system is used to deliver the beam
to the treatment room and to the patient. While only fixed beam lines were employed in the
beginning of proton therapy, gantry systems that allow the irradiation of the patient from
many beam ports were constructed later to provide more degrees of freedom. To direct
the beam towards the patient, the gantries have to be equipped with bending magnets
with large magnetic fields. This leads to an enormous size: the gantry at the Paul Scherrer
Institute (Villigen) has a diameter of 4 m (Pedroni et al. 1995), which is even relatively small
compared to other installations. The actual beam scanning in the two lateral directions
is accomplished by magnetic deflection systems (e.g. Kanai et al. 1980). This can be
done either using two sweeping magnets (Lorin et al. 2000), or by combining one sweeping
magnet with a moveable patient couch to cover the second direction (Pedroni et al. 1995).
One can distinguish between spot scanning and raster scanning methods. While the beam
is only switched on at discrete positions in spot scanning, raster scanning involves the
continuous scanning of the beam along a predefined trajectory. Ideally, the treatment
planning software should account for the properties of the specific scanning system at the
planning stage, although it is possible to convert discrete intensity maps into continuous
scanning patterns later on (Trofimov and Bortfeld 2003).
2.3 Dose calculation and optimization
For the dose calculation in proton therapy a number of methods and algorithms are avail-
able (e.g. Hong et al. 1996, Carlsson et al. 1997, Deasy 1998, Russell et al. 2000; for an
overview see Oelfke 2002). They are either based on broad beam or pencil beam models,
or they rely on Monte Carlo techniques. Although more time consuming, Monte Carlo
simulations are superior if inhomogeneities in the patient geometry have to be taken into
account. A promising compromise are methods that involve two-dimensional scaling of
pencil beams (Szymanowski and Oelfke 2002, 2003).
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Due to the increased degrees of freedom for scanning techniques, inverse treatment
planning is required in IMPT. This means that the individual weights of all beam spots
have to be optimized by a computer program using appropriate optimization algorithms.
In this work, a research version of the inverse planning tool KonRad is employed, which
provides an option for IMPT with discrete spot scanning techniques (Nill et al. 2000, Nill
2001, Nill et al. 2004). The dose calculation in KonRad is done by a finite pencil beam
algorithm using the concept of the Dij matrix (see below and Nill 2001).
2.3.1 The concept of the Dij matrix
The Dij matrix (sometimes also called influence matrix) is a computational method to
separate the dose calculation from the optimization. Let us consider a set of N beam spots
that irradiate a patient or a phantom. At a certain voxel i, several of these beam spots
will contribute to the dose Di. Now Dij shall denote the dose contribution of beam spot j
in voxel i per unit fluence of beam spot j. The total dose Di in voxel i is then given by
Di =
N∑
j=1
Dijwj, (2.4)
where wj denotes the relative fluence weight of beam spot j.
The elements of the Dij matrix can be filled by any desired dose calculation algorithm.
Even complicated or time consuming methods like Monte Carlo could be used, since the
Dij matrix has to be calculated only once for a given treatment situation. During the
iterations of the optimization loop, where the weights w = {wj} are determined, the actual
dose distribution can be updated easily and very fast by equation (2.4), which does not
need any complicated computational procedures. Another advantage of the precalculated
Dij matrix approach is the possibility for multi-modality treatment planning, since sub-
sets of the beam spots can utilize different radiation modalities, and the respective Dij
elements can be calculated by different algorithms (Nill 2001).
2.3.2 Optimization strategies
The aim of the optimization is to find a set of weights w so that the resulting dose distribu-
tion best matches the desired clinical objectives. The latter are usually given as constraints
in terms of the physical dose, e.g. minimum and maximum dose levels for the PTV (DPTVmin
and DPTVmax ) to ensure a homogeneous dose in the PTV, and maximum doses for organs at
risk (DOARmax ). Mathematically, the optimization is done by minimizing a so-called objective
13
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function by iterative algorithms. These algorithms can be either deterministic (e.g. the
Newton gradient technique, which is implemented in KonRad), or stochastic methods like
simulated annealing. An overview of optimization techniques can be found in Webb (2001,
chap. 5.5), and a comparison of three algorithms using Newton’s method in Holmes and
Mackie (1994).
A typical example of an objective function for one PTV and one organ at risk is
F (w) = FPTV(w) + FOAR(w) (2.5a)
with
FPTV(w) = νPTVmin
∑
i∈PTV
[
C+(D
PTV
min −Di(w))
]2
+νPTVmax
∑
i∈PTV
[
C+(Di(w)−DPTVmax )
]2
(2.5b)
and
FOAR(w) = νOARmax
∑
i∈OAR
[
C+(Di(w)−DOARmax )
]2
, (2.5c)
which is called the standard quadratic objective function. The user-defined penalty factors
ν specify the relative importance of the respective dose constraints, and the C+ operator
selects only those voxels that violate the given constraint, i.e. C+(x) = x for x > 0 and
C+(x) = 0 otherwise (Oelfke and Bortfeld 2001, Oelfke 2002). This objective function can
easily be extended to more complex situations, e.g. with more than one organ at risk.
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Chapter 3
Three-Dimensional LET Calculations
3.1 Introduction
Besides other parameters like dose, tissue type and the biological endpoint, the RBE de-
pends on the local energy spectrum (e.g. Belli et al. 1989, Skarsgard 1998, Kraft 2000).
The latter is often referred to as “radiation quality” and can be characterized in first order
by the linear energy transfer LET (ICRU 1970). Thus it is of interest to provide three-
dimensional LET distributions in addition to the dose distributions. They can help to
localize high LET regions, where the greatest variations of RBE are expected, or they can
serve as input for the estimation of three-dimensional RBE distributions (see chapter 4).
Additionally, the LET calculations also have potential applications for predicting the re-
sponse of LET dependent dosimeters, e.g. in gel dosimetry (cf Ba¨ck et al. 1999, Heufelder
et al. 2003) or alanine detectors (cf Palmans 2003).
While the LET for monoenergetic protons is easily obtained from tables (ICRU 1993),
the calculation of the mean local LET for realistic proton spectra, e.g. in spread-out Bragg
peaks, is a more complicated task. This can in principle be accomplished by Monte Carlo
simulations (Seltzer 1993, Berger 1993, Wouters et al. 1996). However, these simulations
are still very time consuming and not well suited to iterative treatment planning, where
LET distributions have to be calculated several times until the optimum treatment plan
is found (cf chapter 5). A fast method for three-dimensional LET calculations is therefore
presented in this work. It is based on an analytical model for the LET distribution along
the central axis of broad proton beams in water and allows fast calculations of LET with
simple parameters, namely the beam energy and the width of the initial energy spectrum.
This chapter is organized as follows: first, I will recall some definitions of LET (sec-
tion 3.1.1), explain how LET distributions can be superimposed (section 3.1.2) and moti-
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vate the use of the dose averaged LET (section 3.1.3). In section 3.2, I will then describe
the methods for three-dimensional LET calculations, before some results are presented
(section 3.3) and discussed (section 3.4).
3.1.1 Definitions of LET
The term “linear energy transfer,” which is in this work applied to protons only, is widely
used to describe radiation quality. There are currently several definitions of LET in use,
so I will first give an overview of some of these concepts.
All LET definitions are based on the stopping power. The total linear stopping power
S for a given material is the sum of the linear collision stopping power Scol and the linear
radiative stopping power Srad. As the latter can be neglected for therapeutic protons
(ICRU 1993), we get
S = Scol =
(
dE
dl
)
col
, (3.1)
where dE is the energy lost by a proton in traversing a distance dl (ICRU 1998). Sometimes
Scol denotes the electronic collision stopping power Sel only, i.e. the stopping power due to
Coulomb interactions with electrons (ICRU 1993). In our context S shall always include
the stopping power due to Coulomb interactions with nuclei (sometimes termed Snuc), i.e.
S = Sel + Snuc.
ICRU report 60 (1998) defines the linear energy transfer as the restricted linear elec-
tronic stopping power L∆, where electrons released with kinetic energies greater than ∆
are treated separately. The unrestricted linear energy transfer L∞ equals again Sel.
Besides that, the term LET is also employed to describe a mean value of the stopping
power. This mean can be calculated either along the track of a single particle (ICRU
1970, Hall 2000) or by averaging the stopping powers of all particles at a certain point in
a radiation field (ICRU 1970, Berger 1993). The latter approach will be used in this work:
LET is here defined as a local mean of the stopping power S to quantify the local radiation
quality.
Let us consider a point x in a radiation field. The protons contributing to the fluence
at x will usually not be monoenergetic and will therefore have different stopping powers.
In this situation it is useful to define an average stopping power or LET. As usual, average
values can be defined in several ways. The two most common implementations are the
track averaged LET and the dose averaged LET. The track averaged LET is the mean
value of S weighted by fluence (or particle tracks, hence the name), i.e. it is the arithmetic
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mean of S for all protons present. For the dose averaged LET the stopping power of each
individual proton is weighted by its contribution to the local dose.
The situation is further complicated, if several different species of charged particles are
present at the point x. In proton therapy this is almost always the case, as secondary
particles produced in nonelastic nuclear interactions include charged particles that are
heavier than protons (e.g. He ions). One can then calculate a mean LET for each particle
type separately, using the respective stopping powers and energy spectra, and average
them to get a total LET (Seltzer 1993, Berger 1993). However, as a simplification only
the “pure” proton LET will be considered in this work, i.e. the LET contributions of all
charged particles other than protons will be disregarded.
As shown above, the track and dose averaged LET depend on the local energy spectrum
at the point x. In the following, the spectrum will be described in terms of the particle’s
residual range rather than its energy. This is possible because there is a unique relation
between the energy and the residual range (cf equation (2.2)) in the continuous slowing
down approximation (CSDA). A respective range-energy table was published in ICRU
report 49 (1993).
Let r denote the residual range of an individual proton at a point x, and ϕr(x) the
local particle spectrum at this point, i.e. ϕr(x)dr gives the fluence of protons at x with
residual ranges between r and r + dr. The total particle fluence at x will be
∫∞
0
ϕr(x)dr.
The track averaged linear energy transfer Lt(x) at x is then given by
Lt(x) =
∫ ∞
0
ϕr(x)S(r)dr∫ ∞
0
ϕr(x)dr
, (3.2)
where S(r) is the stopping power of protons with residual range r. Similar to the notation
used by Berger (1993), the dose averaged linear energy transfer Ld(x) at x is defined as
Ld(x) =
∫ ∞
0
ϕr(x)S
2(r)dr∫ ∞
0
ϕr(x)S(r)dr
. (3.3)
For monoenergetic protons both the track averaged and the dose averaged LET equal the
stopping power S.
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3.1.2 Superposition of LET distributions
For spread-out Bragg peaks and/or beams from more than one direction the LET distri-
butions for the superposition of several beam spots or beams have to be computed. Let
us therefore consider n beams or beam spots with local spectra ϕr,j(x) (j = 1 . . . n) at a
point x. The total spectrum ϕr(x) will just be the sum of ϕr,j(x) for all beams. As the
summation and the integration can be permuted, equations (3.2) and (3.3) become
Lt(x) =
n∑
j=1
∫ ∞
0
ϕr,j(x)S(r)dr
n∑
j=1
∫ ∞
0
ϕr,j(x)dr
(3.4)
and
Ld(x) =
n∑
j=1
∫ ∞
0
ϕr,j(x)S
2(r)dr
n∑
j=1
∫ ∞
0
ϕr,j(x)S(r)dr
. (3.5)
This means that one can calculate the numerator and denominator in equations (3.2) and
(3.3) separately for each beam and add them up before performing the final division.
Let us now denote the individual LETs of all beam spots by Lt,j(x) and Ld,j(x) and
their contribution to the total absorbed dose D(x) by Dj(x). The individual fluences are
then given by Φj(x) = ρDj(x)/Lt,j(x) (cf equation (2.3)). Thus one can express the track
averaged and dose averaged LET by
Lt(x) =
n∑
j=1
Lt,j(x)Φj(x)
n∑
j=1
Φj(x)
=
ρ
Φ(x)
n∑
j=1
Dj(x) (3.6)
and
Ld(x) =
n∑
j=1
Ld,j(x)Dj(x)
n∑
j=1
Dj(x)
=
1
D(x)
n∑
j=1
Ld,j(x)Dj(x). (3.7)
So for every point x the dose averaged LET is the mean of the individual LETs Ld,j(x) of
all beam spots, weighted by their contributions Dj(x) to the total absorbed dose at x.
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D1 D2 D =D1 +D2 Φ1 Φ2 Lt Ld
(Gy) (Gy) (Gy) (109/cm2) (109/cm2) (keV/µm) (keV/µm)
1 1 2 0.62 0.042 1.9 8.0
10 1 11 6.2 0.042 1.1 2.3
1 10 11 0.62 0.42 6.6 13.7
Table 3.1: Comparison of track averaged and dose averaged LETs for mixed irradiation
with two different stopping powers (S1 = 1 keV/µm and S2 = 15 keV/µm) for three ratios
of the respective doses D1 and D2.
3.1.3 Motivation for the use of the dose averaged LET
In the previous sections, two LETs were introduced: the track averaged and the dose
averaged LET. Although both of them are currently in use, the question arises which one
of the two should be used in our context, i.e. for the estimation of RBE distributions.
For monoenergetic protons, Lt(x) and Ld(x) equal each other. Differences occur a)
if the local energy spectrum of the protons becomes broader (as it is the case in every
realistic proton beam), and b) if the protons at x come from several beam spots with
different energies (e.g. for SOBPs or scanning techniques) either from the same direction
or from multiple beam angles. We are now looking for a reasonable way to define a mean
stopping power or LET that resembles the overall situation at that point. In other words:
what is the mean stopping power 〈S(x)〉 so that a dose D(x) of monoenergetic protons
with 〈S(x)〉 has the same biological effect as the initial set of polyenergetic protons with
a total dose of D(x)?
Let us consider a brief example: a certain voxel of water (density ρ = 1 g/cm3) shall
be irradiated by two proton beams with stopping powers of S1 = 1 keV/µm and S2 =
15 keV/µm, respectively. We assume that these values do not change within the voxel.
Table 3.1 shows the resulting LETs for three scenarios with different dose weighting. The
corresponding fluences Φ1 = ρD1/S1 (cf equation (2.3)) and Φ2 as well as the total fluence
Φ are also given. Obviously, in all cases Lt and Ld lie between S1 and S2. For equal doses
(D1 = D2), one would intuitively expect 〈S〉 to be more or less in the middle between
S1 and S2, which is fulfilled by Ld, but not by Lt. For D1 = 10 × D2, the situation is
dominated by the low LET radiation, so 〈S〉 should be similar to S1. This condition is
satisfied by both Lt and Ld. In the third case, where D2 = 10×D1, 〈S〉 should be close to
S2; this is only true for the dose averaged LET (table 3.1). Intuitively, the dose averaged
LET therefore seems to be more appropriate for our purpose. This is supported by the fact
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that the dose (rather than the fluence) is used in radiotherapy as the primary indicator of
the biological effect, which makes dose weighting also reasonable for second order effects.
Another more important argument will become apparent in section 4.2.3 when the RBE
model is explained, and shall be discussed here only briefly. When the linear-quadratic
(LQ) model (Kellerer and Rossi 1978) is applied to mixed irradiations with different LET,
it is reasonable to use the dose averaged mean of the α parameter (Zaider and Rossi 1980).
In chapter 4, I will express α as a linear function of LET, and under that restriction the
dose averaged mean of α is equivalent to α calculated as a function of the dose averaged
LET.
So in this work, I will concentrate on the dose averaged LET, although I will also
provide some formulas for the track averaged LET for the sake of completeness. For the
RBE calculations in this work (chapters 4 and 5), only the dose averaged LET is used.
3.2 Methods
I will now derive an algorithm for three-dimensional LET calculations (Wilkens and Oelfke
2004) for realistic treatment plans and patient geometries, i.e. based on computed to-
mography (CT) data sets. In order to obtain the LET distribution in analogy to dose
calculations, we will need i) a model for the LET on the central axis for a single beam spot
or Bragg peak in a water phantom (section 3.2.1, see also Wilkens and Oelfke 2003), ii)
lateral LET distributions to get off-axis values (section 3.2.2), and iii) a rule for scaling the
LET with the radiological depth to account for tissue inhomogeneities (section 3.2.3). The
implementation of this algorithm in the treatment planning software KonRad is described
in section 3.2.4.
3.2.1 LET along the central axis
In this section, I will present an analytical model for the LET distribution along the
central axis of proton beams (section 3.2.1.1). After that, I will describe the Monte Carlo
simulations that were performed to validate the analytical model (section 3.2.1.2).
3.2.1.1 The analytical LET model
Protons in matter undergo Coulomb interactions (with electrons and nuclei) and nonelastic
nuclear interactions, leading to target fragmentation and secondary particles. For the
analytical LET model only Coulomb interactions of primary protons as the most frequent
interaction process are considered. Especially around the peak and at the distal edge
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of the Bragg curve, where the largest increase in LET is expected, the absorbed dose is
dominated by Coulomb interactions. The dose due to secondary particles can be neglected
at or behind the Bragg peak (Paganetti 2002). Nonelastic nuclear interactions occur mostly
in the entrance region of the Bragg curve, where the LET is generally low and varies only
slightly. However, secondary particles such as alpha particles may have high stopping
powers and therefore high LET contributions. Hence they might influence the biological
effect (Paganetti 2002), albeit experimental evidence has not yet been firmly established.
Let us now consider a single broad beam of protons in a water phantom. The derivation
of a model for the LET along the central axis (Wilkens and Oelfke 2003) can be done in very
close analogy to studies presented by Bortfeld (1997), where an analytical approximation
for the proton depth dose curve was developed. Let ϕr(z) denote the local proton spectrum
in residual range r at depth z. To calculate the LET values according to (3.2) and (3.3)
we will have to evaluate the following three integrals:
Φz :=
∫ ∞
0
ϕr(z)dr,
〈S〉z :=
∫ ∞
0
ϕr(z)S(r)dr and (3.8)
〈S2〉z :=
∫ ∞
0
ϕr(z)S
2(r)dr.
The track averaged and dose averaged LET can then be calculated by
Lt(z) =
〈S〉z
Φz
and Ld(z) =
〈S2〉z
〈S〉z . (3.9)
Before solving these three integrals, we will have a closer look at the spectrum ϕr(z) and
the stopping power S(r).
Local proton spectra First an expression for the local proton spectrum ϕr(z) with
respect to residual range r is derived. Let R0 be the mean initial range of the protons
entering the water phantom with a fluence Φ0 at the phantom surface (z = 0). At depth
z ≥ 0, we will assume a Gaussian spectrum with standard deviation σ(z) around the mean
residual range R0 − z:
ϕr(z) =
Φ0√
2piσ(z)
e−(r−(R0−z))
2/2σ2(z). (3.10)
The total fluence
∫∞
0
ϕr(z)dr at depth z will be Φ0 at z = 0, 12Φ0 at z = R0, and 0
for z À R0. There are two contributions to σ(z): the range straggling width σmono(z) for
monoenergetic protons and the machine dependent width of the initial energy spectrum of
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the incident protons, which is usually not monoenergetic, but has a certain width σE. The
latter is usually given in MeV but can be translated into a standard deviation of range by
using the range-energy relationship.
Although the range straggling width σmono(z) strongly depends on z, as straggling
increases with depth, it is a good approximation to use a constant σ instead of σ(z)
(Bortfeld 1997). Then (3.10) becomes
ϕr(z) =
Φ0√
2piσ
e−(r−R0+z)
2/2σ2 . (3.11)
For σmono, Bortfeld (1997) derived the expression 0.012 · R0.9350 , where σ and R0 are given
in cm. To transform σE from energy to range, he linearized the range-energy relationship
r = αEp (2.2) around the mean initial energy E0. This yields
σr = σE
dr
dE
∣∣∣∣
E=E0
= σEαpE
p−1
0 = σEα
1/ppR
1−1/p
0 . (3.12)
The total σ can then be calculated from σmono and σr:
σ2 = σ2mono + σ
2
r . (3.13)
A more precise model of the initial energy spectrum would not only consider the main
peak but also the so-called tail towards lower energies, which can be found in many treat-
ment machines. This relatively small tail is neglected because the protons of the tail will
not reach the depth of R0 due to their lower energy, i.e. they only affect the entrance region
of the Bragg curve, where LET variations are small. However, they will increase the LET
in this region slightly without influencing it at or behind the Bragg peak.
Fluence reduction Equation (3.10) does not take into account any absorption of pro-
tons. But the proton fluence decreases with increasing depth due to nonelastic nuclear
interactions. As one can assume a linear reduction with depth (Lee et al. 1993, Bortfeld
1997), a better approximation for the local proton spectra than (3.10) would be
ϕr(z) =
Φ0√
2piσ
1 + βr
1 + βR0
e−(r−(R0−z))
2/2σ2 , (3.14)
with β = 0.012 cm−1.
The analytical LET calculations can be performed with these improved spectra without
extraordinary mathematical effort. However, it turned out that β did not have any relevant
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Figure 3.1: Proton stopping powers in water as a function of residual range. The circles
represent the values published in ICRU report 49 (1993). The solid and dotted lines are
the basic parametrization by Bortfeld (1997) using a single power law and the result of the
regularization with R = 2 µm, respectively.
impact on the resulting LET distributions. This can be understood by the mathematical
structure of equations (3.2) and (3.3): due to the definitions of LET as a ratio the absolute
number of particles is not very important but rather the relative spectra. Although the β
terms do not completely cancel mathematically, it is obvious that reducing the number of
particles will not affect the LET values much. Therefore β was neglected in all other LET
calculations presented in this work.
Stopping power Proton stopping powers were published in ICRU report 49 (1993). The
total stopping power due to Coulomb interactions with electrons and with nuclei is plotted
in figure 3.1. According to a fit by Bortfeld (1997), a simple power law can be used as an
analytical expression for the stopping power:
S˜(r) =
1
pα1/p
r1/p−1, (3.15)
with p = 1.77 and α = 0.0022 cm·MeV−p (cf section 2.1.1).
This is a good fit for residual ranges between approximately 2 µm and 50 cm (see
figure 3.1). Ranges above 50 cm in water are not needed in radiation therapy, but the
deviations below 2 µm can become important for LET calculations. As protons with
ranges around 2 µm and smaller (corresponding to energies well below 1 MeV) do not
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contribute much to the absorbed dose, this fit works well for dose calculations. However,
such low-energy protons have an impact on the LET calculations, especially due to the
singularity of S˜(r) at r → 0, which has no physical counterpart in reality. To avoid this
singularity, the stopping powers for low ranges have to be modeled more precisely. To
keep the formula simple and in the mathematical form of power laws, a regularization is
performed: S˜(r) is substituted by SR(r), which is the mean stopping power along the last
bit of length R of the path, i.e. the mean of S˜ in the interval [r, r +R]:
SR(r) =
1
R
∫ r+R
r
S˜(r′)dr′ =
1
Rα1/p
[
(r +R)1/p − r1/p] . (3.16)
The result for R = 2 µm is shown in figure 3.1. The value of R was adjusted by comparing
our analytical model to Monte Carlo simulations (see section 3.3.1.2). For S2(r), which is
needed for the calculation of the dose averaged LET, a similar regularization is performed:
S2R(r) =
1
R
∫ r+R
r
S˜2(r′)dr′ =
1
Rα2/pp(2− p)
[
(r +R)2/p−1 − r2/p−1] . (3.17)
For the following calculations, SR(r) and S2R(r) are used for S(r) and S
2(r).
Calculation of LET By employing our expressions for ϕr(z) and the stopping power in
(3.8), a short calculation presented in appendix A leads to the following results:
Φz =
Φ0√
2pi
e−ζ
2/4D−1(ζ),
〈S〉z = Φ0√
2piσRα1/p
[
σ1+1/pΓ(1 + 1
p
)D˜1+1/p(ξ, ζ)−R( 12R)1/pe−(ζ+ξ)
2/8
]
, (3.18)
〈S2〉z = Φ0√
2piσRα2/pp(2− p)
[
σ2/pΓ( 2
p
)D˜2/p(ξ, ζ)− 2( 12R)2/pe−(ζ+ξ)
2/8
]
,
with D˜ν(ξ, ζ) = e−ξ2/4D−ν(ξ)−e−ζ2/4D−ν(ζ) and ζ = (z−R0)/σ, ξ = (z−R0−R)/σ. Here
Γ(x) is the gamma function and Dν(x) are the parabolic cylinder functions (Gradshteyn
and Ryzhik 1994). These functions are tabulated (Abramowitz and Stegun 1972) or can
be easily computed by computer programs. The track averaged and dose averaged LET
can now be calculated by inserting these results into (3.9). If z, R0, R and σ are given in
cm, Lt and Ld will have units of MeV/cm. Multiplying these values by 0.1 yields units of
keV/µm.
Although the introduction of the parabolic cylinder functions seems to be quite elegant
from a mathematical point of view, it must be noted that this is certainly not the only way
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to approach these integrals. They can as well be evaluated numerically, which would allow
for even more complicated integrands, as they were no longer restricted to power laws.
The calculations presented above can be performed similarly without the regularization
of S˜(r), i.e. by using S˜(r) and S˜2(r) in (3.8) instead of SR(r) and S2R(r). For the dose
averaged LET, this would yield
Ld(z) =
σ1/p−1Γ( 2
p
− 1)D1−2/p(ζ)
pα1/pΓ( 1
p
)D−1/p(ζ) . (3.19)
However, this simplified approach would significantly overestimate the LET (see sec-
tion 3.3.1.2) and can therefore not be used for LET calculations.
3.2.1.2 Monte Carlo simulations of LET
Although LET and related quantities can be measured by microdosimetric procedures
(ICRU 1983, Coutrakon et al. 1997), Monte Carlo simulations are used in this work for the
evaluation of the proposed analytical model. They offer a simple way to obtain local energy
spectra in a given geometry, which can then be used to calculate LET distributions. The
Monte Carlo code GEANT 3.21 (CERN 1994) and the hadron generator FLUKA (Fasso`
et al. 1993, 1994) are well suited for this problem (Gottschalk et al. 1999, Paganetti and
Gottschalk 2003).
A broad beam of protons with a field size of 5×5 cm2 was simulated in a homogeneous
water phantom (20×20×50 cm3). The initial energy spectrum of the protons was Gaussian
with a mean of E0 and a standard deviation of σE. The initial momentum of the protons
was perpendicular to the phantom surface. Further studies were performed with different
field sizes, even down to an infinitely thin pencil beam.
Electronic and hadronic interactions were considered, and all secondary particles pro-
duced in primary and subsequent interactions were tracked. All protons (regardless whether
they were primary protons or produced in any nuclear reaction) were scored for the local
proton spectra. An important parameter for the Monte Carlo simulations was the cutoff
energy for protons, as the low-energy protons have a significant influence on the LET due
to their high stopping powers. Especially with a cutoff of 1 MeV, which is sufficient in
dose calculation (Szymanowski and Oelfke 2002), the LET is underestimated compared to
simulations with lower cutoffs. Several values were tested and it turned out that a reduc-
tion of the cutoff energy further than 0.25 MeV did not cause any further changes in the
LET. Therefore a cutoff energy of 0.25 MeV was used for the comparison of LET values
with the analytical model. To obtain the local energy spectrum at depth z on the central
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axis of the beam, the energies of all those protons were registered that traversed a plane
of 1×1 cm2 perpendicular to the central axis at depth z. For the pencil beam, this scoring
area was reduced to 1×1 mm2. The resolution of the energy bins was 0.25 MeV.
If φi(z) denotes the number of protons in energy bin i (i = 1 . . . N) and the stopping
powers Si (corresponding to the mean energy of bin i) are taken from ICRU report 49
(1993), the track averaged and dose averaged LET are calculated by
LMCt (z) =
N∑
i=1
φi(z)Si
N∑
i=1
φi(z)
and LMCd (z) =
N∑
i=1
φi(z)S
2
i
N∑
i=1
φi(z)Si
. (3.20)
3.2.2 Lateral LET distributions
In general, the LET increases at the field border because there are more scattered protons
that have less energy and therefore higher stopping powers than the protons on the central
axis. To quantify this effect, Monte Carlo simulations were done in the same geometry
as described in the last section. Now protons were also scored at off-axis positions in a
1 mm grid, and proton spectra were obtained to get lateral LET distributions. This was
also done for different field sizes, i.e. for broad beams and for pencil beams. As expected,
both the track averaged and the dose averaged LET increased outside of the field with
increasing lateral distance to the central axis. These results are shown in section 3.3.2 and
in Wilkens and Oelfke (2004).
It was found that this increase is relatively small compared to the steep rise of LET along
the central axis. As it was seen in cell survival experiments (e.g. Belli et al. 1993, Wouters
et al. 1996), small variations in LET are not expected to affect the RBE significantly. The
important effect that has to be considered in treatment planning is certainly the steep rise
of LET along the central axis, while the lateral variations might be neglected. Therefore
it is a good approximation to use a laterally constant LET, i.e. to assume that the LET
in water (Lw) at depth z and lateral distance d to the central axis depends only on the
depth:
Lw(z, d) = Lwcax(z). (3.21)
This approximation can be made for the track averaged as well as for the dose averaged
LET, and it makes three-dimensional LET calculations very simple (cf section 3.2.4).
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3.2.3 LET in inhomogeneous media
The LET calculations described above are valid for water phantoms only. In the next
step we will therefore consider tissue inhomogeneities given by CT data sets. For a single
beam, the LET at a given voxel in the CT cube can be obtained from the LET in water
by substituting the depth with the water equivalent depth η(z), i.e. the radiological path
length. The latter is computed by a raytracing algorithm through the CT cube. This
requires the relative stopping powers Srel for each voxel, which can be obtained from CT
Hounsfield units by appropriate calibration curves (Schneider et al. 1996, Schaffner and
Pedroni 1998). Together with (3.21) we then get
L(z, d) = Lwcax(η(z)). (3.22)
Note that this is still “LET in water” and not “LET in medium”, corresponding to the
dose which is usually reported as dose to water rather than dose to medium (Liu et al.
2002). However, while dose to water and dose to medium are fairly similar for biological
tissues, LET in water and LET in medium can differ significantly. LET in medium can be
calculated from L(z, d) by multiplying with Srel for the respective voxel media (as long as
Srel is assumed to be independent of the energy).
The greatest deviations between LET in water and LET in medium will be in high
density materials, i.e. in bone. But the RBE of protons in bone has not been investigated
much yet, and we are primarily interested in more water-like tissues like most tumours
and organs at risk. For those tissues, LET in water and LET in medium are more similar.
Therefore it is justifiable to use only LET in water, as long as we keep in mind that we
underestimate the LET in high density tissues. Consequently, only LET in water will be
used throughout this work in analogy to the common practice for the dose.
3.2.4 Integration into KonRad
The combination of all aspects mentioned in the sections above yields a fast algorithm for
three-dimensional LET calculations, which is very similar to currently implemented finite
pencil beam dose calculation algorithms. This LET calculation algorithm was integrated
into a research version of the inverse treatment planning tool KonRad, which already
provided an option for intensity modulated proton therapy (Nill et al. 2000, Nill 2001,
Oelfke and Bortfeld 2001). In the following, I will describe how the dose averaged LET is
calculated in KonRad. The track averaged LET was also implemented in a similar way.
27
3. Three-Dimensional LET Calculations
Energy Range R0 Initial width σE of energy spectrum
(MeV) (cm) (MeV)
160 17.63 0.0
200 26.2 2.0
250 37.9 1.0
Table 3.2: Parameters for the analytical LET model (range R0 and width σE of the initial
energy spectrum) that were used to obtain the LET distributions for three proton energies as
input data for KonRad. All calculations were done with the regularization of the stopping
power using R = 2 µm.
For the LET calculations, a matrix named Lij is used in analogy to the influence
matrix Dij for the dose (see section 2.3.1, and Nill 2001, p 7). The values in the Lij matrix
represent the LET that one would see in voxel i if only the j-th beam spot were present.
To calculate the entries in the Lij matrix (section 3.2.4.2), look-up tables for the LET are
required that correspond to the given depth dose curves for the dose (section 3.2.4.1). The
three-dimensional LET distribution (i.e. Li for every voxel i) can then be obtained from Lij
using the weights wj of all beam spots (and the Dij matrix, see below in section 3.2.4.3).
Finally, the LET cube is written to a file (in analogy to the dose cube files), and a
normalization value is given to translate the numbers in the file into units of keV/µm. The
LET cube can be further processed as desired, e.g. to get “LET-volume-histograms” (like
dose-volume-histograms, cf Webb 1993, pp 17–20).
3.2.4.1 Input data for KonRad
The dose calculation in KonRad is a finite pencil beam algorithm (Nill 2001, p 30), which
uses precalculated depth-dose curves for various proton energies. For every depth-dose
curve, a corresponding curve for the LET along the central axis in water (Lwcax(z)) is now
read into KonRad. In principle, the results for Lwcax(z) from either the analytical model or
Monte Carlo simulations can be used as input data. In the current work, LET distributions
computed with the analytical model are used. The respective parameters for the range and
the width of the initial energy spectrum are given in table 3.2. They were obtained by
fitting the dose from the analytical model (cf Bortfeld 1997) to the existing depth-dose
curves in KonRad. One has to note that this set of input data does not correspond to any
existing proton accelerator in particular. It just resembles a fictitious machine with three
energies (160, 200 and 250 MeV) and a continuous range shifter. For each beam spot,
KonRad chooses the best energy to match the desired range.
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voxel i
central axis of beam spot j
patient surface
beam spot j
z
Figure 3.2: Geometric setup for LET calculations: The LET from beam spot j at voxel i
(Lij) is computed using the radiological path length η(z) along the central axis of the beam
spot j at the geometric depth z.
3.2.4.2 Calculation of the Lij matrix
The Lij matrix is calculated and stored exactly parallel to the Dij matrix. This saves
time, as many computational procedures like the raytracing through the CT cube have
to be done only once for both matrices. The following steps must be performed for every
voxel i and beam spot j to calculate Lij:
• Calculate Dij as usual (see section 2.3.1, and Nill 2001, p 34). During this process,
the radiological path length η(z) along the central axis at the geometric depth z is
already computed (figure 3.2, cf section 3.2.3).
• If Dij > 0, then Lij = Lwcax(η(z)). This is done by interpolating the LET values
of the input data (section 3.2.4.1) for the energy of beam spot j, taking the range
shifter setting for beam spot j into account. This formula is so simple because of the
assumption of a laterally constant LET.
• If Dij = 0, then Lij = 0, i.e. the Lij matrix is only calculated for non-zero Dij
elements.
To save memory space, the Lij matrix is stored as a compact matrix L˜ij. The two
matrices are connected by
Lij = l · L˜ij, (3.23)
where l is a calibration factor, which is set to 0.01 keV/µm. The entries of L˜ij are stored as
two byte variables (range 0–32 767). This corresponds to LET values from 0 to 328 keV/µm
with a resolution of 0.01 keV/µm. As the Dij matrix needs six bytes per entry (four for the
voxel index and two for a similarly compressed dose value, Nill 2001, p 15), the introduction
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of the Lij matrix requires only 33% more memory space than the Dij matrix alone. Modern
personal computers can easily handle that requirement.
3.2.4.3 Calculation of the three-dimensional LET distribution
Once the weights wj of the beam spot are established in the optimization process, three-
dimensional LET calculations can be made. Let Li denote the product of the dose averaged
LET (Li) and the dose (Di) at voxel i. According to equation (3.7), Li can be written as
Li =
∑
j
LijDijwj. (3.24)
This sum can be computed easily in the same way as the dose distribution Di =
∑
j Dijwj
(cf equation (2.4)). Due to the precalculated values of Lij and Dij, this operation can
be done very fast, which will be useful when LET calculations are integrated into the
optimization loop in chapter 5. There one will often need only the product of LET and
dose, which is now easily accessible as Li. If the actual LET distribution is desired, Li can
be obtained as
Li =
{Li/Di for Di > 0,
0 for Di = 0.
(3.25)
3.3 Results
Now analytical LET distributions for several beam configurations are presented and com-
pared to Monte Carlo simulations, first on the central axis and later also for lateral LET
distributions. After that, I will compare three-dimensional LET distributions for spot
scanning techniques in IMPT, in particular for the full 3D modulation and for the distal
edge tracking (DET).
3.3.1 LET along the central axis
The analytical LET model was compared with the results of the Monte Carlo simulations
for a variety of cases, including energies up to 250 MeV. In the following, I will show
the results for several exemplary proton energies (mostly 160 MeV and 70 MeV), and
the impact of the width of the initial energy spectrum is investigated. Eventually, LET
distributions will also be calculated for a spread-out Bragg peak.
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Figure 3.3: LET distributions for broad beams of 160 MeV (a) and 250 MeV (b) protons
in water. Track averaged and dose averaged LET obtained by Monte Carlo simulations
(squares and triangles) are compared with the analytical model (lower and upper solid lines,
respectively). The relative dose distributions are given in arbitrary units (dotted lines).
3.3.1.1 LET for high energy beams
First some results for high energy proton beams with initial energies of 160 and 250 MeV are
presented, as those are typical values for the treatment of deep seated tumours. Figure 3.3a
shows the depth dependence of the track averaged and dose averaged LET along the
central axis of a broad proton beam (160 MeV) in a water phantom, both calculated with
the analytical model as well as with Monte Carlo simulations (with 3.2×107 simulated
incident protons). The energy spectrum at the phantom surface was Gaussian with a width
of σE = 0.5 MeV around the mean energy of 160 MeV. The Monte Carlo simulations for
this energy yielded a mean range (given by the 80% dose at the distal edge) of 17.36 cm,
which does not agree exactly with the range of 17.65 cm given in ICRU report 49 (1993).
This is due to the fact that GEANT 3.21 uses slightly different stopping powers than those
in ICRU report 49 (Szymanowski and Oelfke 2002). To be in accordance with the Monte
Carlo simulations, a value of R0 = 17.36 cm was used in the analytical model instead of
17.65 cm. The relative dose distribution obtained by Monte Carlo simulations is given by
the dotted line in arbitrary units. In figure 3.3b, the same situation is shown for a 250 MeV
proton beam (R0 = 37.4 cm, σE = 0.5 MeV, simulation with 2×107 incident protons).
As expected the LET increases very slowly in the entrance region of the beam, but
rises steeply at the end of the range. In the entrance region the track averaged and dose
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averaged LET are almost equal, but at greater depths the dose averaged LET exceeds the
track averaged LET considerably. The analytical model agrees well with the Monte Carlo
simulations. The maximum deviations were around 0.5 keV/µm.
Let us have a closer look at the entrance region of the 160 MeV beam: In the first 10 cm
of depth, where the LETs range between 0.5 and 1.0 keV/µm, the dose averaged LET ob-
tained by the Monte Carlo method was slightly higher than the predictions of the analytical
model (up to 0.2 keV/µm). This is due to a high LET contribution from secondary protons
produced by nonelastic nuclear interactions, which are included in the Monte Carlo simu-
lations but neglected in the analytical model: by switching off the production of secondary
particles in the Monte Carlo code, these differences completely vanished. Consequently,
this effect is more pronounced for higher energies (differences up to 0.5 keV/µm were ob-
served for a 250 MeV beam, figure 3.3b), whereas it is reduced for smaller energies (cf
section 3.3.1.3).
In figure 3.3 and in all following figures, the Monte Carlo LET is given only at depths
where the dose is at least 0.1% of the maximum dose. Further beyond the peak, the number
of particles becomes so small that Monte Carlo simulations need an enormous amount of
incident protons to yield sufficient statistics. However, in some of the figures one can still
see deviations due to poor statistics at the last two or three data points, although the dose
is above 0.1% of the peak value. The analytical model is in principle able to calculate LET
at any depth, and the analytical LET is therefore plotted up to slightly greater depths than
the last Monte Carlo points. For practical purposes this will probably never be needed, as
the number of particles at depths far beyond the peak reaches almost zero, and the term
LET becomes meaningless for practical applications.
3.3.1.2 Impact of the regularization
The LET distributions in figure 3.3 were calculated with R = 2 µm. To illustrate the impact
of this parameter in the regularization of S˜(r) described in section 3.2.1.1 (cf equations
(3.16) and (3.17)), dose averaged LET distributions for several values of R are shown in
figure 3.4 in comparison to the Monte Carlo simulations with an initial energy of 160 MeV,
R0 = 17.36 cm and σE = 0.5 MeV as above.
The dotted line shows the LET one would get without the regularization, i.e. by using
S˜(r) from (3.15) directly for the LET calculations. The derivation of the analytical LET
becomes then a bit easier than with the regularization, but leads to similar formulas with
different indices of the parabolic cylinder functions (equation (3.19)). However one would
significantly overestimate the LET at the distal edge as compared with the Monte Carlo
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Figure 3.4: Influence of the parameter R of the regularization of the power law fit for the
stopping power: analytical distributions for the dose averaged LET for 160 MeV protons
without regularization (dotted line) and with R = 1 µm, 10 µm and 100 µm (solid lines A,
B and C) in comparison to the Monte Carlo simulations (triangles).
simulations (figure 3.4), because of the purely mathematical singularity of S˜(r) at very low
residual ranges.
By introducing the regularization, the stopping power is modeled more precisely to
correspond to the “real” stopping powers given in ICRU report 49. For increasing values
of R the increase in LET at the distal dose edge becomes less and less pronounced. This
behaviour is shown in figure 3.4 for R = 1 µm, 10 µm and 100 µm. For depths smaller
than about 16.5 cm, the regularization does not have any effects on the LET. It turned out
that a value of R = 2 µm agreed best with the Monte Carlo simulations, both for the dose
averaged and for the track averaged LET. Such a “range cutoff” of 2 µm corresponds to a
proton energy of 0.13 MeV, which is fairly similar to the Monte Carlo cutoff of 0.25 MeV.
Still having in mind that the first fit S˜(r) agreed with ICRU 49 for residual ranges down
to approximately 2 µm (see section 3.2.1.1), the use of R = 2 µm seems to be reasonable.
3.3.1.3 LET for low energy beams
In figure 3.5 LET distributions for a proton beam with an initial energy of 70 MeV are
shown, which is a typical energy used for the treatment of intraocular tumours. The LET
is calculated in water with R = 2 µm and σE = 0.5 MeV. R0 was set to 4.02 cm to fit the
mean range of protons in the Monte Carlo simulations, which were done for 2×107 incident
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Figure 3.5: LET distributions for a broad beam of 70 MeV protons in water (σE =
0.5 MeV). Track averaged and dose averaged LET obtained by Monte Carlo simulations
(squares and triangles) are compared with the analytical model (lower and upper solid line,
respectively). The relative dose distribution is given in arbitrary units (dotted line).
protons in this case. The general behaviour of the LETs is quite similar to the LETs for
160 MeV. However, the absolute LET values at the distal edge are higher compared to
the 160 MeV beam. The deviations between the analytical model and the Monte Carlo
simulations in the entrance region, which were discussed for 160 MeV, are much smaller
for 70 MeV, as secondary protons are less important at lower energies. The maximum
deviations were around 0.5 keV/µm at depths greater than 4 cm.
3.3.1.4 Variation of the initial energy spectrum
Next we will investigate the impact of the width σE of the initial energy spectrum. We will
use the situation of the 70 MeV beam above (σE = 0.5 MeV), and compare it with two
other values of σE: 0 and 2 MeV. These LET distributions are shown in figure 3.6. Again
the relative dose distributions are shown in arbitrary units. As σE gets larger, the shape of
the Bragg peak becomes broader and the maximum is shifted towards smaller depths. The
range, i.e. the 80% dose at the distal edge, was always 4.02 cm. The dose averaged LETs
for all three values of σE are displayed together in figure 3.7. The LETs are the same at
depths smaller than 3 cm and agree well with the Monte Carlo simulations, therefore these
depths were not included in figures 3.6 and 3.7. The higher σE, the lower the maximum
LET values become, and the less steep is its increase at the end of the range. However, the
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Figure 3.6: LET distributions for 70 MeV protons in water with σE = 0 MeV (a) and
σE = 2 MeV (b). Track averaged and dose averaged LET obtained by Monte Carlo sim-
ulations (squares and triangles) are compared with the analytical model (lower and upper
solid lines, respectively). The relative dose distributions are given in arbitrary units (dotted
lines).
increase starts earlier, so the region with an LET higher than 5 keV/µm is considerably
bigger for σE = 2 MeV than for 0 or 0.5 MeV. Nevertheless the monoenergetic limit σE = 0
can be used to estimate the maximum LET for a given beam energy.
3.3.1.5 LET for a spread-out Bragg peak
As soon as the analytical model was established and validated for a single Bragg peak, it
is easy to superimpose several Bragg peaks for more complex situations. In figure 3.8 an
example for a 6 cm spread-out Bragg peak (SOBP) is given, which consists of 13 single
peaks of 160 MeV that were modulated by a passive range shifter. The positions of the
peaks (i.e. the maxima of the dose) are indicated by small vertical lines. The weights of
the peaks were obtained by an optimization algorithm presented by Gardey et al. (1999).
The dose was computed with the analytical model developed by Bortfeld (1997). The LET
distributions for every peak were calculated with the analytical LET model (R = 2 µm)
and the final LET distributions are obtained according to equations (3.4) and (3.5).
The dose averaged LET is again always greater than the track averaged LET, as it
was observed for single beams. At the beginning of the SOBP plateau at around 7 cm
depth, there is an increase of the dose averaged LET due to slow protons originating from
the Bragg peak at 7.2 cm. On the other hand the track averaged LET does not show
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Figure 3.7: Dose averaged LET calculated with the analytical model (solid lines) in com-
parison to Monte Carlo simulations (triangles) for 70 MeV beams in water with varying
width of the initial energy spectrum (σE = 0, 0.5 and 2 MeV for curves A, B and C,
respectively). The range (4.02 cm) is indicated by the vertical line.
a significant increase at the beginning of the plateau. Along the SOBP plateau, both
track averaged and dose averaged LET keep increasing, because the fraction of low-energy
protons with high stopping powers rises. At the distal edge of the SOBP the LET shows
a similar behaviour as for a single peak, because this region is dominated by the protons
of the peak at 13.2 cm only.
3.3.1.6 LET dependence on field size
Additional Monte Carlo simulations were performed for different field sizes, and in particu-
lar for an infinitely narrow pencil beam. In the Bragg peak region, no significant deviations
of the LET on the central axis as a function of the field size were seen. While the track
averaged LET did not change in the entrance region either, there were small but systematic
differences in the dose averaged LET in that region. Here Ld was slightly lower (within
±0.5 keV/µm) for the pencil beam than for broad beams (cf exemplary data for Lcax in
table 3.3). This is again (cf section 3.3.1.1) an effect due to secondary protons. These
low energy secondaries are less frequent on the central axis of the pencil beam, because
they are scattered away in different directions. In broad beams, this is compensated by
secondaries that are scattered onto the central axis from neighbouring parts of the field.
Therefore the dose averaged LET on the central axis is slightly higher for broad beams
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Figure 3.8: LET distributions for a spread-out Bragg peak, which consists of 13 single
peaks. The positions of the peaks are indicated by the small vertical lines. The track
averaged and dose averaged LET (lower and upper solid line, respectively) are calculated
with the analytical LET model. The dotted line shows the dose distribution in arbitrary
units.
than for the pencil beam. In total, the LET distribution along the central axis was more
or less independent of the field size (within ±0.5 keV/µm), even for pencil beams. The
analytical LET model can therefore be used for beam spots of any size, i.e. for SOBPs as
well as for scanning techniques with narrow beams.
3.3.2 Lateral LET distributions
In further Monte Carlo studies, lateral LET distributions for proton beams with different
field sizes in water were obtained. Within the treatment field, a constant LET was observed
(figure 3.9). This is in agreement with a study by Paganetti (1998), where no lateral RBE
variations within a spread-out Bragg peak field for the treatment of ocular tumours were
found (beam energy 68 MeV). The LET increases outside of the field, because there are
more scattered and therefore slower protons with higher stopping powers. However, this
increase is very moderate in terms of absolute values: table 3.3a gives numbers for the dose
averaged LET on the central axis (Lcax) and at the lateral positions of 50%, 20% and 5%
of the central axis dose (L50, L20 and L5, respectively) for a broad 160 MeV beam (peak
position at 17.2 cm depth, beam width 5 cm). The difference between L5 and Lcax was well
below 2 keV/µm for all depths. Again, this behaviour was investigated for different field
sizes, and no qualitative differences as a function of the field size were found. Even for a
37
3. Three-Dimensional LET Calculations
a) Broad beam b) Pencil beam
Depth Lcax L50 L20 L5 Lcax L50 L20 L5
(cm) (keV/µm) (keV/µm)
5.0 0.8 0.9 1.0 2.1 0.6 0.7 0.7 0.7
10.0 0.9 0.9 1.0 1.2 0.8 0.8 0.8 0.9
17.0 4.3 4.3 4.7 5.9 3.9 4.0 4.1 4.7
17.5 10.7 10.7 11.1 11.3 10.4 10.6 10.9 11.0
Table 3.3: Lateral values of the dose averaged LET at several depths for a broad beam (a)
and a pencil beam (b) of 160 MeV protons, obtained by Monte Carlo simulations (2×108
incident protons each). LET values are given for the central axis (Lcax) and for the lateral
positions of 50%, 20% and 5% of the central axis dose.
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Figure 3.9: Lateral LET profiles (solid lines) for a broad 160 MeV proton beam of 5 cm
width in water. The relative dose profiles (dotted lines) are given in arbitrary units for
comparison. Both LET and dose were obtained by Monte Carlo simulations (with 2×108
incident protons) and are given for depths of z = 10 cm (green) and z = 17 cm (red)
slightly before the Bragg peak at 17.2 cm.
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Figure 3.10: Distributions of dose (left) and LET (right) in a transversal slice through
the isocentre for distal edge tracking. The colour scales are normalized to the median PTV
dose (100%) and to 100% = 5 keV/µm, respectively.
pencil beam (table 3.3b), the increase at the field border was very similar or even smaller
than for broad beams. This means that only small errors are introduced if a laterally
constant LET is used instead of the “real” lateral LET distributions as seen in the Monte
Carlo studies. This justifies the assumption of a laterally constant LET, which was made
in section 3.2.2.
3.3.3 Three-dimensional LET distributions
Three-dimensional LET distributions were calculated for a variety of clinical cases and for
different dose delivery techniques (Wilkens and Oelfke 2004). Here the focus will be on the
comparison of LET distributions for two spot scanning techniques for intensity modulated
proton therapy: the 3D modulation, where beam spots are placed over the entire target
volume, and distal edge tracking (DET), where only beam spots whose Bragg peak is
positioned directly on the distal edge of the target are considered (Lomax 1999). Due to
the substantially reduced number of beam spots, the DET technique offers advantages in
both computing time and delivery effort compared to the 3D modulation (Nill 2001, Nill
et al. 2004).
As an example of the LET calculations, two treatment plans are shown for a patient with
a clivus chordoma. The patient geometry and the optimization constraints are described in
more detail in chapter 5, where an extensive study on this case including RBE calculations
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Figure 3.11: Dose (left) and LET distribution (right) in a transversal slice through the
isocentre for the full 3D modulation technique. The colour scales are normalized to the
median PTV dose (100%) and to 100% = 5 keV/µm, respectively.
is presented. Here, I will just demonstrate the LET algorithm and the differences in
LET for the two scanning techniques, i.e. for distal edge tracking (figure 3.10) and for
the 3D modulation (figure 3.11). In both cases five coplanar beams were chosen for the
treatment of the planning target volume (PTV, thick red line). For every field, beam spots
with initial energies up to 200 MeV were placed with a lateral distance of 6 mm. Their
individual weights were optimized with the inverse planning tool KonRad using its standard
quadratic objective function and an iterative gradient method. The objectives were to
deliver a homogeneous dose to the PTV, and to spare the brainstem (thick green line) as
the most important organ at risk as much as possible. The physical dose distributions (left
side in figures 3.10 and 3.11) were very similar for both techniques. The high dose region
was highly conformal to the PTV, while the brainstem was mostly spared from dose.
The corresponding distributions of the dose averaged LET are shown on the right sides
of figures 3.10 and 3.11 (colour scales normalized to 100% = 5 keV/µm). The LET values
within the PTV varied considerably for DET, with high LET regions at the border of
the PTV. The highest values were even outside of the PTV in the normal tissue. For
the 3D modulation technique, a more homogeneous distribution on a higher LET level
was found. This is also apparent in the LET-volume-histograms (figure 3.12, in analogy
to dose-volume-histograms). The mean LET in the PTV was 2.1 keV/µm for DET and
3.5 keV/µm for the 3D modulation, with a maximum LET in the PTV of 7.3 keV/µm and
40
3.4 Discussion
LET (keV/µm)
0 2 4 6 8
v
o
lu
m
e
 (
%
)
0
20
40
60
80
100
PTV
brainstem
Figure 3.12: LET-volume-histograms for PTV (red) and brainstem (green) for the two
treatment plans shown in figures 3.10 and 3.11, i.e. for the DET technique (solid lines)
and for 3D modulation (dotted lines).
5.1 keV/µm, respectively. The brainstem as the primary organ at risk received substantially
higher LET values for DET compared to the 3D modulation (figure 3.12).
3.4 Discussion
3.4.1 LET along the central axis
The presented analytical model for the proton LET along the central axis is able to calculate
LET distributions for clinical proton energies, taking range straggling and the machine
dependent initial energy spectrum into account. The predictions of the model agree within
±0.5 keV/µm with the Monte Carlo simulations. The main assumptions of the model were
thereby justified, particularly the restriction to Coulomb interactions, the neglect of the
fluence reduction, and the use of a depth independent σ. The Gaussian approximation of
the proton spectra was successful even at depths greater than the CSDA range.
The observed LET distributions showed a slow increase along the entrance region of the
beam, and then a very steep increase at the Bragg peak. As expected (ICRU 1970), the
dose averaged LET always exceeded the track averaged LET. The absolute LET values at
the distal edge were higher for 70 MeV than for 160 MeV, so one would expect a greater
effect of this high LET region for the low energy beams, as it was already pointed out
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by other authors (Paganetti and Schmitz 1996, Skarsgard 1998). The narrower the initial
energy spectrum, the higher LET values were observed at the distal edge. However, for
broader spectra the increase of LET starts at smaller depths, resulting in an extended
region of increased LET.
With the analytical model it was further possible to calculate LET distributions for
spread-out Bragg peaks. The LET increases along the SOBP plateau, leading to an
increased relative biological effectiveness at the end of the SOBP, which was found in
experimental and theoretical studies (Wouters et al. 1996, Paganetti and Schmitz 1996,
Biaggi et al. 1999, Paganetti and Goitein 2000). Dose averaged LET distributions for
SOBPs were also calculated by Seltzer (1993) using Monte Carlo techniques, giving sep-
arate curves for “primary-protons-only” and “primaries-plus-nuclear-secondaries.” While
the former agreed very well with our LET model as well as with Monte Carlo simulations by
Wouters et al. (1996), there were significant differences compared to the latter, namely in
the entrance region and in the SOBP plateau, where the total LET including all secondary
particles was considerably higher than the LET of primary protons only.
One has to note that the LET distributions presented in this work do not fully account
for secondary particles due to nonelastic nuclear interactions. These are completely ne-
glected in the analytical model, and even in the Monte Carlo simulations only secondary
protons (which have the highest contribution to the dose of all secondaries) are taken into
account. Heavier secondary particles like He ions are not considered, although they can
have considerably higher stopping powers than protons. However, these secondaries are
most important in the entrance region, where the energy is high enough to produce a sig-
nificant number of nonelastic nuclear interactions. At or behind the Bragg peak, secondary
particles can be neglected (Paganetti 2002). The role of these secondaries in assessing the
biological effect is a question of the respective RBE model rather than LET — and for
exact RBE calculations alpha particles might have to be included.
Furthermore, the tail of the initial energy spectrum towards low energies was considered
neither in the analytical model nor in the Monte Carlo simulations. This might affect the
LET in the entrance region as well, but not the LET around the peak, as the protons of
the tail have smaller ranges. The LET distributions calculated with the analytical model
should therefore correspond well to the reality in the region around the Bragg peak, whereas
the LET in the entrance region might be underestimated.
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3.4.2 Three-dimensional LET calculations
By combining the analytical model for the LET along the central axis and our studies to
lateral LET distributions, a method for fast three-dimensional LET calculations on CT
data sets has been developed. It accounts for tissue inhomogeneities and can be applied to
state-of-the-art proton dose delivery techniques, as it works for broad beams as well as for
thin pencil beams. However, one must be aware that due to the assumption of a laterally
constant LET, the LET distributions might be slightly underestimated.
In particular, the LET algorithm was used to compare LET distributions for distal
edge tracking (DET) and for the full 3D modulation in intensity modulated proton ther-
apy. While very similar dose distributions can be accomplished with both techniques,
considerable differences in the LET distributions were observed. Whereas the 3D modula-
tion yielded more or less homogeneous LET distributions in the PTV, elevated LET values
were found at the border of the PTV for DET.
From cell survival experiments it is known that the RBE for protons increases with LET
up to an LET value around 30 keV/µm, and decreases for higher LETs (see chapter 4).
As the maximum LET values found in our study were around 15 keV/µm, we are in the
increasing branch only and can therefore expect elevated RBE values in the high LET
regions. For distal edge tracking, this might result in an inhomogeneous biological effect
in the PTV as well as in increased damage to organs at risk or normal tissue outside of
the PTV. From this point of view, DET seems to be unfavourable compared to the full
3D modulation. However, in chapter 5 optimization methods that compensate this effect
will be presented.
At the current point it is still under investigation whether the observed differences in
LET are clinically significant, i.e. whether the potential variations in RBE are big enough
to be observable in clinical studies. One has to keep in mind that even extreme LET values
in normal tissue or organs at risk may be meaningless on the scale of clinical observations,
especially if the dose is very low. Moreover, the RBE is certainly not a function of LET
alone, but depends as well on other parameters like the dose and the tissue type. Finally
it is the product of RBE and dose that matters, so high RBE values might be tolerated
well as long as the corresponding dose values are relatively small. With the RBE model
that will be described in chapter 4, we can address this question again in chapter 5.
Nevertheless, the choice of the dose delivery technique obviously influences the LET
distribution and therefore the expected biological effect. Thus, the physical dose should not
be the only criterion for comparing treatment plans or different spot scanning techniques
in proton therapy. For this purpose, our algorithm for LET calculations is a useful tool to
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locate regions of high or low LET, which might in particular help to avoid the exposure of
organs at risk to high LET values. The application of three-dimensional LET distributions
for fast RBE calculations and even for the optimization of the biological effect will be
discussed in the following chapters.
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Chapter 4
The Phenomenological RBE Model
4.1 Introduction
While the physical properties of therapeutic proton beams are well known (cf chapter 2),
there are still some unsolved questions regarding the biological effect of protons, which is
often expressed in terms of the so-called relative biological effectiveness (RBE). Today,
most clinical centres use a constant RBE of 1.1 although there is experimental evidence
that the RBE is not constant, but depends on dose and on the radiation quality, i.e. the
local proton energy distribution. This is very obvious for in vitro experiments with cell
cultures (e.g. Belli et al. 1993, Wouters et al. 1996, Skarsgard 1998). On the other hand,
the observed RBE variations for in vivo systems are much smaller, and in most cases a
constant RBE of 1.1 seems to be clinically acceptable (Paganetti et al. 2002). But even
in vivo there is an increase in RBE at the end of the proton range (Gueulette et al. 2001)
that should be accounted for in treatment planning (Paganetti et al. 2002).
In this thesis, the potential clinical impact of a variable RBE for different treatment
techniques in intensity modulated proton therapy is investigated. This requires a reliable
RBE model that is simple enough to allow very fast calculations of three-dimensional RBE
distributions. Especially for the integration of the RBE model into the optimization loop,
the calculation speed becomes a very important issue. Existing RBE models based on track
structure theory (Butts and Katz 1967, Katz et al. 1971, Scholz and Kraft 1994, Scholz
et al. 1997, Paganetti and Goitein 2001) are quite elaborate and need long computing times,
which renders them not particularly well suited for inverse planning. The aim of this work
is therefore to develop a simple and fast method for approximative RBE calculations,
which can still reproduce the basic effects of a variable RBE as observed in radiobiological
experiments.
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It is not our goal to design a new mechanistic theory of RBE, since such theories can
still only be a crude approximation to the whole complexity of the radiobiological effects
of ionizing radiation. At the current point, we therefore see our only chance in using a
phenomenological model based on experimental results, mainly from in vitro studies with
cell cultures. Thus we propose a simplified RBE model based on the linear-quadratic
model, which describes the RBE as a function of dose, linear energy transfer (LET) and
phenomenological tissue parameters. In its current form, the model is intended only for
protons and not for heavier charged particles. For the latter, the radiobiology becomes more
complex and it will thus be more difficult to find a simple phenomenological approach (see
chapter 6).
In this work I will concentrate — as an example — on in vitro experiments for V79
Chinese hamster fibroblasts, as there are many data available in the literature for this cell
line. After the presentation of the RBE model (section 4.2), RBE values obtained with
the new model will be compared to published results (section 4.3) and implications for the
shape of spread-out Bragg peaks (SOBPs) will be discussed.
4.2 Methods
The most important dependencies of the RBE of proton beams are those on depth, dose
and tissue type or cell line, which have been investigated experimentally and theoretically
by many authors (e.g. Hall et al. 1978, Bettega et al. 1979, Blomquist et al. 1993, Wouters
et al. 1996, Denekamp et al. 1997, Tang et al. 1997, Paganetti 1998, Gerweck and Kozin
1999, Kraft 2000). For the dependence on depth it is of course not the depth itself that
matters, but rather the energy or the energy spectrum of the protons, which changes with
depth. This is often described with the term “radiation quality” and quantified by the
linear energy transfer (LET). Accordingly, the LET will be used in addition to the dose
to characterize the radiation field. Methods for three-dimensional calculations of the dose
averaged LET were already presented in chapter 3. Goodhead et al. (1992) showed that
in general the radiation quality cannot be described by the LET alone, as they found
different RBE values for protons and alpha particles with the same LET. However, since
we consider only protons, the LET concept can be used for our purpose. While the dose
dependency of RBE is clearly seen in vitro (e.g. Hall et al. 1978, Wouters et al. 1996), it
seems to be less pronounced in vivo (e.g. Tepper et al. 1977, Gueulette et al. 2001). Among
other reasons, this might be due to the fact that most in vivo studies were done at low
LET (e.g. in the entrance region or in mid SOBP), whereas the greatest effects of the dose
dependency (and of a variable RBE in general) can be expected for higher LET values, i.e.
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in the distal dose falloff. The RBE further depends on the choice of the reference radiation
(section 4.2.2.3) and on the biological endpoint (e.g. cell survival). Therefore the endpoint
needs to be specified when tissue specific parameters for the RBE model are derived.
4.2.1 The relevant LET range in proton therapy
A brief overview over LET definitions and methods for three-dimensional LET calculations
were given in chapter 3. Since the RBE model has to cover only therapeutically relevant
LET values, this range in LET will now be specified. Protons of 250 MeV (the highest
energy used in therapy) have a stopping power of 0.39 keV/µm, and for decreasing energy
the stopping power rises to a maximum of 83 keV/µm at 0.08 MeV, before it drops down
again (ICRU 1993). However, in therapeutic beams one will rarely find voxels exposed
to monoenergetic protons of 0.08 MeV only, as range straggling broadens the spectrum
even for initially monoenergetic beams. For E0 = 70 MeV and σE = 0, data in figure 3.7
show that the dose averaged LET does not exceed 30 keV/µm, at least for those depths
where the dose is above 0.1% of the maximum dose. And this is even an extreme case:
the LET values at the distal edge decrease for higher initial energies (due to increased
range straggling), as well as for greater values of σE (cf section 3.3). Of course there are
single protons with higher stopping powers, but they do not contribute much to the dose
averaged LET. Since a laterally constant LET is assumed (cf section 3.2.2), the off-axis
LET values will not be higher than on the central axis. For therapeutic proton fields with
initial beam energies between ∼70–250 MeV, we can safely restrict our RBE model to dose
averaged LETs in the range 0.3–30 keV/µm.
4.2.2 The phenomenological RBE model
The biological response to radiation is often described by the linear-quadratic (LQ) model
(Kellerer and Rossi 1978), which characterizes the biological system by two parameters α
and β. The surviving fraction SF of cells at a certain dose D is then given by
SF = exp(−αD − βD2). (4.1)
There are other models as well, but in many cases the LQ model reproduces the exper-
imental results fairly well. It is therefore reasonable to use the LQ model, at least in a
phenomenological rather than in a mechanistic way. Let us now consider two survival
curves as a function of dose for the same biological system, but for two different radiations:
a reference radiation with parameters αx and βx, and a proton beam with αp and βp. The
47
4. The Phenomenological RBE Model
RBE can then be calculated easily, as RBE is just defined as the ratio of the doses required
to yield the same survival level. The RBE at a certain proton dose Dp is then given by
RBE(Dp, αx, βx, αp, βp) =
√
α2x + 4βxDp(αp + βpDp)− αx
2βxDp
. (4.2)
In the limits of very low and very high doses, this can be simplified to
lim
Dp→0
RBE(Dp, αx, βx, αp, βp) =
αp
αx
and lim
Dp→∞
RBE(Dp, αx, βx, αp, βp) =
√
βp
βx
. (4.3)
Of course one can also express the RBE as a function of the reference dose Dx or the
corresponding biological effect (i.e. SF ) instead of the proton dose Dp. These formulas are
all equivalent and can be used as desired. Similar expressions were also presented by other
authors (e.g. Joiner and Field 1988, Hawkins 1998, Dale and Jones 1999). The RBE in
(4.2) depends on dose, which has to be the dose per fraction in a multifraction regime. The
tissue and endpoint dependence is determined by the α and β parameters for the reference
radiation and for protons. However, the values of αp and βp are not fixed, but they depend
on the radiation quality or LET of the respective proton beam. This was investigated in
many experiments, so we can now look at the dependencies of αp and βp on LET.
4.2.2.1 The dependence of αp on LET
Figure 4.1 shows data for αp as a function of the dose averaged LET for the survival of
V79 Chinese hamster cells in vitro from many different experiments with protons. Up to
∼30 keV/µm, αp increases with LET, and decreases for higher LETs. But as LET values
above 30 keV/µm are not needed for practical purposes in clinical proton therapy (cf
section 4.2.1), we can concentrate on the low LET region and assume a linear dependence
of αp on the LET L:
αp(L) = α0 + λL. (4.4)
Fur further simplification, one could even set α0 := αx, although we do not employ this
restriction at this point. Unfortunately, there are no studies in the low LET region below
∼3 keV/µm that report both αp and the LET at the point of the measurement. The best
fit to the data for V79 cells was obtained for α0 = 0.1 Gy
−1 and λ = 0.02 µm keV−1 Gy−1.
If — for any reason — the LET region above 30 keV/µm also had to be modeled, one
solution could be to use the linear function below the maximum at Lmax, and a 1/L de-
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Figure 4.1: Experimental results for the LQ parameters αp and βp as a function of
LET for the survival of V79 Chinese hamster cells in vitro: (a) αp vs. LET, (b) βp vs.
LET (◦ Perris et al. 1986; M Goodhead et al. 1992; O Blomquist et al. 1993; ¥ Belli
et al. 1993; ¤ Folkard et al. 1996; •Wouters et al. 1996; N Waheed et al. 1997; ♦ Belli
et al. 1998; ¨ Schettino et al. 2001). Error bars in LET are included as far as they
were reported. In (a), a linear fit according to equation (4.4) with α0 = 0.1 Gy
−1 and
λ = 0.02 µm keV−1 Gy−1 was added, while the dotted line in (b) corresponds to a constant
βp according to equation (4.6) using βx = 0.0298 Gy
−2 (Tilly et al. 1999).
pendence above Lmax, corresponding to a constant value of the “inactivation cross section”
αp(L)× L:
αp(L) =
{
α0 + λL for L ≤ Lmax,
(α0 + λLmax)Lmax/L for L > Lmax.
(4.5)
Hawkins (1998) also suggested a linear dependence like in (4.4), and found good agree-
ment with experimental data for several cell lines in the LET region below 50 keV/µm
(Hawkins 2003). Tilly et al. (2002) used a similar expression for tissues with αx/βx below
5 Gy, and an exponential dependence of αp on LET for higher αx/βx. A linear dependence
on LET was also predicted and discussed by Neary (1965) and Schmid et al. (1997) for
chromosome aberrations. Tang et al. (1997) reported an increasing αp with depth and
therefore with LET for the survival of CHO cells in a 65 MeV SOBP. Chapman et al.
(1977) also saw an increasing αp with LET for V79 cells under irradiation with heavier
ions (He, C, Ne, Ar).
4.2.2.2 The dependence of βp on LET
The LET dependence of βp (figure 4.1b) is not as clear as the situation for αp. While
Belli et al. (1998) found an increasing βp for LET from 7.7 to 20 keV/µm, Folkard et al.
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(1996) reported decreasing values. Also for other experimental situations, many different
opinions on this question can be found in the literature: Courdi et al. (1994) saw an
increasing βp with LET for human melanoma cells, and Chapman et al. (1977) reported a
slightly increasing βp for increasing LET with heavy ions. Barendsen performed extensive
studies on the LET dependence of the LQ parameters (1994, 1997) and finally suggested
a value of approximately 1.5–2.0×βx for βp at high LET (2000). On the other hand, Tang
et al. (1997) did not see an increase of βp with LET in their study, and a constant βp is
frequently discussed (Neary 1965, ICRP 1989, Hawkins 1998, Dale and Jones 1999, Jones
and Dale 2003). Tilly et al. (2002) used a constant βp for L≤20 keV/µm, and a linear
decrease for higher LETs. No significant variations in βp at L≤6 keV/µm were observed
for chromosome aberrations (Schmid et al. 1997).
Unfortunately, there are not much data for βp at high LET values (above ∼20 keV/µm).
This is because the measured survival data at these LET values usually do not show a
distinct shoulder, so many authors fitted the survival data just to a pure exponential curve
(exp(−αD)). However, this does not necessarily mean that βp is zero. At these high LET
values, where αp is large, one would need to go to very high doses (even above 10 Gy) to
determine a small βp component accurately. But at these doses, the number of surviving
cells becomes very small, which makes measurements of βp at high LET extremely difficult.
But this also means that βp has not much influence at high LET, especially at thera-
peutic levels for the dose per fraction (well below 10 Gy), where the variations in αp are
much more important. We therefore think that it is justified to use a constant βp, which
for simplicity shall be the βx of the reference radiation, i.e.
βp(L) := βx. (4.6)
At least at low LET, this seems to be in agreement with the data in figure 4.1.
By inserting equations (4.4) and (4.6) into (4.2) we finally get
RBE(Dp, L, α0, λ, αx, βx) =
√
α2x + 4βxDp(α0 + λL+ βxDp)− αx
2βxDp
. (4.7)
Again, similar formulas can be obtained for RBE as a function of Dx or of the biological
effect rather than Dp. In particular, the RBE for a given surviving fraction SF is
RBE(SF, L, α0, λ, αx, βx) =
√
α2x − 4βx lnSF − αx√
(α0 + λL)2 − 4βx lnSF − α0 − λL
. (4.8)
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4.2.2.3 Reference radiation
The RBE obviously depends on the choice of the reference radiation. Cell experiments for
the determination of RBE values were mostly done either with 200 or 250 kVp X-rays, or
with 60Co gamma-rays as reference. In the following, I will give all RBE values relative
to 60Co gamma-rays, since they are similar to high energy photons from clinical linear
accelerators, which are commonly used in conventional radiation therapy. For V79 cells,
we will therefore use αx = 0.112 Gy
−1 and βx = 0.0298 Gy−2 (Tilly et al. 1999). However,
one must be aware that errors in αx and βx lead to considerable uncertainties in the RBE
values, although the biological effect in terms of the surviving fraction SF in a proton
beam is determined by α0, λ, βp, D and L only.
4.2.3 Mixed LET irradiations
Most of the data in figure 4.1 are for monoenergetic protons (apart from Blomquist et al.
1993 and Wouters et al. 1996). However, in clinical practice of proton therapy, one will
almost always find polyenergetic beams (as in SOBPs) and/or the superposition of differ-
ent beam spots from different directions. This makes mixed irradiation experiments very
interesting in this context. Tilly et al. (1999) compared several cell survival models for a
mixed LET experiment with V79 cells irradiated with nitrogen ions and 60Co gamma-rays.
They found that the track structure model (Katz et al. 1971), the microdosimetric (LQ)
model (Kellerer and Rossi 1978, Zaider and Rossi 1980) and the lesion additivity model
(Lam 1987) could all predict the experimental results within the uncertainties of the mea-
surement. The approach of Zaider and Rossi (1980) was also used by Belli et al. (1997)
for protons and was successfully applied to carbon beams (e.g. Kanai et al. 1997, Schaffner
et al. 2000). It describes the effect of two (or more) irradiations with different LET by
“dose averaged” means of the respective α and
√
β values. In the region below 30 keV/µm,
this is equivalent to our model, where the total αp is calculated as a linear function of the
dose averaged LET. This indicates that mixed irradiation effects for protons of different
LET are reasonably modeled in our approach.
4.3 Results
4.3.1 Comparison with experimental RBE values
In figure 4.2, RBE values for the survival of V79 cells calculated with our model are com-
pared to experimental data from the literature (Blomquist et al. 1993, Folkard et al. 1996,
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Figure 4.2: RBE values (relative to 60Co) for the survival of V79 cells, irradiated with
protons of different LET. The experimental data for two survival levels (◦ 10%, • 50%) are
from Blomquist et al. (1993), Folkard et al. (1996), Wouters et al. (1996) and Belli et al.
(1998). RBE values that were reported relative to 200 kVp (Belli et al. 1998) or 240 kVp
X-rays (Folkard et al. 1996) were corrected to 60Co by applying a dose independent factor
of 1.1 (Spadinger and Palcic 1992). The RBE values from equation (4.8) for the 10% and
50% survival level are given by the dotted and solid lines, respectively.
Wouters et al. 1996, Belli et al. 1998) for two survival levels (10% and 50%), corresponding
to doses of 7.1 and 3.3 Gy 60Co gamma-rays. For the phenomenological RBE model, the
values for αx, βx, α0 and λ that were given in the previous section were employed. The
experimental data are either as stated in the original publications, or they were derived
from the α and β values for protons and the reference radiation given in the respective
papers. Where no error bars for the RBE were reported, they were calculated from the
errors in α and β, as far as those were given. For LETs below 30 keV/µm, the RBE
increases with LET for a given survival level. Independently of LET, the RBE is higher
for higher survival levels, i.e. for lower doses.
4.3.2 Application of the RBE model to SOBPs
The RBE model was applied to two SOBPs with maximum energies of 70 MeV and
160 MeV (figure 4.3). Both SOBPs consisted of 15 weighted pristine peaks that were
shifted by different thicknesses of absorbing material. The pristine peaks had an initial
energy spread σE of 0.5 MeV in both cases. The ranges were 4.02 cm (70 MeV) and 17.6 cm
(160 MeV), and the modulation widths (measured between the 90% dose levels) were 2.2 cm
and 7.8 cm, respectively. The physical dose distributions along the central axis (with 2 Gy
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Figure 4.3: (a): Dose (——), RBE (· · · · · ·) and RBE× dose (– – –) for a SOBP with
a maximum energy of 70 MeV (range 4.02 cm), with the corresponding LET in (c). In
panels (b) and (d) on the right, the same distributions are given for a 160 MeV SOBP with
a range of 17.6 cm. RBE values (relative to 60Co) are for the survival of V79 cells and
were calculated with the RBE model described in section 4.2.2.
in the SOBP) are shown in figure 4.3a and b, and the corresponding distributions of the
dose averaged LET in figure 4.3c and d. The LET is low in the entrance region, rises along
the SOBP plateau and increases very steeply at the distal edge. In the 160 MeV beam, the
LET values are lower than for the 70 MeV beam. This is due to the lower stopping power
at high energies in the entrance region, and to increased range straggling in the SOBP
region, which broadens the energy spectrum of the beam, leading to lower values of the
dose averaged LET (cf chapter 3). At every depth, the RBE for the survival of V79 cells
relative to 60Co was calculated according to equation (4.7), using the actual dose and LET
values and the cell parameters (α0, λ, αx and βx) given in section 4.2.2. The RBE and the
product of RBE and dose are shown in figure 4.3a and b for both SOBPs. For RBE× dose,
units of “Cobalt Gray Equivalent” (CGE) were used to indicate that it is a proton dose
which has already been multiplied by the RBE relative to 60Co. The RBE starts around
1 at the beam entrance, increases slowly along the SOBP, and shows a steep increase at
the distal edge. This means that RBE× dose is not flat in the SOBP plateau, but it is
53
4. The Phenomenological RBE Model
70 MeV 160 MeV
SOBP
dose RBE RBE Distal shift RBE RBE Distal shift
(Gy) proximal distal (mm) proximal distal (mm)
1 1.24±0.14 1.93±0.18 0.90±0.06 1.11±0.13 1.60±0.16 2.2±0.2
2 1.18±0.10 1.75±0.13 0.83±0.06 1.08±0.10 1.44±0.11 1.9±0.2
4 1.12±0.07 1.46±0.09 0.70±0.07 1.05±0.06 1.29±0.08 1.6±0.2
8 1.07±0.04 1.28±0.06 0.53±0.06 1.03±0.04 1.18±0.05 1.1±0.2
Table 4.1: RBE values (survival of V79 cells relative to 60Co) at the proximal and distal
edge of the SOBPs shown in figure 4.3 for several dose levels of the SOBP plateau. The
resulting shift in depth of the distal edge between the physical dose and RBE× dose is also
given (evaluated at 80% of the physical dose). The error intervals account for uncertainties
in the parameters α0 and λ.
inclined and shows a clear region of increased effectiveness at the distal edge. Moreover,
the “high dose” region of RBE× dose is extended to slightly greater depths compared to
the physical dose.
The main features of the RBE× dose curve, i.e. the incline of the SOBP and the shift
of the distal edge, were further evaluated for several dose levels (table 4.1). For doses of
1, 2, 4 and 8 Gy, RBE values are given at the proximal and distal edge of the SOBP (at
depths of 1.98 and 3.94 cm for the 70 MeV beam and at 10.5 and 17.4 cm for 160 MeV).
For both energies, the RBE values decrease with increasing dose, and the values at the
distal edge are higher than at the proximal edge. Due to the higher LET values in the low
energy beam, the RBE values are generally higher in that case.
Table 4.1 also quantifies the extension of the high dose region to greater depths, i.e. the
shift of the distal edge of RBE× dose compared to the physical dose. The reported values
are the distance between the two curves measured at the 80% level of the physical dose
given to the SOBP plateau. A constant RBE of 1.1 would result in a dose independent
shift of 0.13 mm (70 MeV) and 0.39 mm (160 MeV) and would clearly underestimate the
values from table 4.1. The effect becomes smaller for greater doses, as the RBE values
decrease with dose. For the 160 MeV case, the absolute values of the shift are more than
twice as high as for the 70 MeV beam, despite of the lower LET and RBE values in the
high energy beam. This is due to the fact that the distal falloff of the physical dose is
much shallower in the 160 MeV beam: the distance between the 80% and 20% levels of
the physical dose in the SOBP is 0.98 mm for the 70 MeV beam compared to 2.9 mm in
the 160 MeV beam, which is due to increased range straggling in the latter case.
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Figure 4.4: Lateral profiles of RBE× dose for a broad 160 MeV proton beam of 5 cm
width at a depth of 17 cm (slightly before the peak at 17.2 cm). The RBE was calculated
using a laterally constant LET (red solid line) as well as using the lateral LET distribution
obtained by Monte Carlo simulations (green), cf figure 3.9. The physical dose is given by
the dotted line.
To estimate the effects of uncertainties in the tissue parameters, potential errors in α0
(±0.02 Gy−1) and λ (±0.002 µm keV−1 Gy−1) were derived from the data in figure 4.1.
The consequences of these errors in a worst case scenario are given in table 4.1. However,
we did not take any possible errors in dose, LET, αx and βx into account, so the real error
will be even larger.
4.3.3 Three-dimensional RBE calculations
The phenomenological RBE model described above can be applied to any point in a radi-
ation field as long as the dose, the dose averaged LET and the relevant tissue parameters
for that point (or voxel) are known. Since three-dimensional distributions of dose and LET
can be calculated (cf section 3.3.3), RBE and RBE× dose can also be obtained in three
dimensions. Such distributions will be shown and discussed for realistic planning studies
in the next chapter.
Here, I will just present an example of lateral profiles for RBE× dose in order to test
the assumption of a laterally constant LET made in section 3.2.2. For a broad beam of
160 MeV (same configuration as described in section 3.3.2, with a peak dose of 4 Gy), lateral
distributions of dose and RBE× dose are given in figure 4.4. The RBE was calculated in
two ways, using i) a laterally constant LET and ii) the lateral LET values obtained by
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Monte Carlo simulations (as shown in figure 3.9). When comparing RBE× dose for the
two methods, only small differences can be seen. The greatest deviations are found in
the low dose region far away from the central axis, where the biological effect is slightly
underestimated when using the constant LET. However, the RBE values at doses below
1 Gy have to be considered with great care since the LQ model might not be valid in that
dose region (see discussion below).
4.4 Discussion
RBE values as a function of the LET were calculated with our model and compared to
experimental results (figure 4.2). In the LET region below 30 keV/µm, our model agreed
with the measurements within the experimental uncertainties. Above ∼15 keV/µm we
overestimate the experimental values slightly, but this is probably acceptable since LET
values below 15 keV/µm are much more common in therapeutic proton beams (cf fig-
ure 4.3). One might argue that the good agreement is not surprising, as the experimental
data in figure 4.2 are basically from the same studies as the data that were used to fit
the tissue parameters (figure 4.1). However, it indicates that the assumptions made in the
derivation of the RBE model are reasonable, in particular the use of a linear function for
αp(L) and a constant βp.
Paganetti and Goitein (2001) gave a very similar figure to figure 4.2, where they com-
pared the experimental RBE data for V79 cells with the predictions of two track structure
models for RBE, namely the Amorphous Track Partition (ATP) model (Butts and Katz
1967, Katz et al. 1971) and the Local Effect Model (LEM, Scholz and Kraft 1994, Scholz
et al. 1997). While the LEM significantly overestimated the RBE for low LET values at
the 50% survival level, the ATP model underestimated the RBE for almost the entire LET
range. For LETs below 30 keV/µm, our model seems to agree better with the experimental
values than the LEM or the ATP model. However, both the LEM and the ATP model
can predict the decrease of RBE at higher LET values, which is beyond the scope of our
model.
Since most of the experimental data in figure 4.2 are from monoenergetic proton beams,
our RBE model is also compared to experiments for more realistic situations like SOBPs.
The main RBE effects for SOBPs, i.e. the increase of the RBE along the SOBP plateau
and the shift of the distal edge, have already been observed by other authors and could
be reproduced by our model. The increasing RBE along the plateau was experimentally
reported for low energy beams (e.g. Wouters et al. 1996, Tang et al. 1997) and for high
energy beams (e.g. Ando et al. 2001), showing a qualitatively similar behaviour to the
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RBE in figure 4.3. Experimental values of the shift of the distal falloff to greater depths
are ∼1 mm for human tumour cells in a 65 MeV SOBP (Bettega et al. 2000), and ∼2 mm
for rat hepatoma H4 cells in a 160 MeV SOBP (Robertson et al. 1975). These values agree
well with those given in table 4.1. In a theoretical study, Paganetti and Goitein (2000)
calculated RBE distributions for the survival of V79 cells in SOBPs with 70 and 120 MeV
beams. For 2 Gy SOBP dose, they found an extension of the SOBP in depth (measured
at the 90% dose level) of 1.2 mm in the 120 MeV beam and 0.8 mm for the low energy
beam, which again corresponds well to the values in table 4.1. They reported that both the
rise of RBE with depth as well as the shift to greater depths is less pronounced for higher
doses, which is also consistent with our observations. This indicates that the dose averaged
LET could successfully be applied as a measure for the radiation quality in polyenergetic
beams. As another test of the RBE model, it would be very interesting to design and
evaluate cell survival measurements for simple cases of mixed radiation fields with protons
of different LET, e.g. to irradiate cells with two well defined proton beams of high and low
LET simultaneously.
As soon as three-dimensional dose and LET distributions are available, the RBE can
be computed at any point in the radiation field. Since the differences in RBE for a laterally
constant or variable LET were small (figure 4.4), the use of a laterally constant LET is
also justified from a radiobiological point of view. However, there is one point that has to
be kept in mind when applying the RBE model to realistic patient geometries: compared
to water phantoms, the distal falloff of the dose can become shallower in inhomogeneous
media due to increased straggling and scattering of the beam when passing through high
density materials like bone (cf Urie et al. 1986). This effect is not included in our dose
calculations, although it might influence the LET and the RBE in the distal part of the
Bragg curve.
It must also be noted that our RBE model has some more limitations. Apart from the
restricted LET range (cf section 4.2.1), the dose range of our model is also limited: since it
is based on the LQ model, we are confined to the validity of the LQ model, which is about
1–10 Gy. Below 1 Gy, the so-called low dose hypersensitivity (Joiner et al. 2001, Schettino
et al. 2001) can cause severe deviations. As typical doses per fraction in proton therapy
are above 1 Gy for the target, this effect is not critical, at least for the optimization of the
dose in the target volume. For organs at risk, where the dose might well be below 1 Gy,
one has to keep this limitation in mind. A special case are treatments of ocular tumours,
where the dose per fraction is often higher than 10 Gy. Here the LQ model must be used
with great care, and small uncertainties especially in the β parameter can lead to large
errors in RBE.
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Another important point is the consideration of secondary particles produced in non-
elastic nuclear interactions, as they can significantly influence the total RBE due to their
high biological effectiveness (Paganetti 2002). Our LET model in its current form can
account for primary and secondary protons only (Wilkens and Oelfke 2003), and heavier
secondaries like alpha particles are not included. This means we are underestimating the
total LET, especially in the entrance region of high energy beams, where most nuclear
interactions occur. However, the RBE model can implicitly account for all secondary par-
ticles, since these secondaries are certainly present in the cell survival experiments that are
used to fit the parameters α0 and λ, even if only a proton LET is reported. Unfortunately,
due to the lack of data for V79 cells in the low LET region below ∼3 keV/µm, this does
not work satisfactorily for the present parameter set. The RBE in the entrance region of
the 160 MeV beam (figure 4.3) is therefore unexpectedly low (below 1.1). On the other
hand, secondary particles can be neglected in the Bragg peak region, which is dominated
by Coulomb interactions. Both LET and RBE are here determined by primary protons
only (Paganetti 2002). In particular, the shift of the distal edge of SOBPs is therefore not
affected by secondary particles.
In this work, tissue parameters for our model were only derived for the survival of
V79 cells in vitro, mainly because there are extensive data in the literature about this cell
line. One must be aware that V79 cells often show higher RBE values than other cell lines
(Paganetti et al. 2002), which makes them a suitable system to study RBE effects. But this
also means that it is difficult to transfer these results to other cell lines or systems, which
can show significantly different behaviour. Especially in in vivo situations, RBE values
closer to 1.1 can be expected. More biological data are therefore required to validate RBE
models in in vivo systems and for clinically relevant endpoints. For practical applications,
great care has to be taken that sufficient and appropriate biological data are used in the
derivation of the tissue parameters. For tissue types other than V79 cells, the parameters
of our RBE model can be derived directly from measurements, ideally for αp(L). While
such data are easily available for various cell lines in vitro (e.g. Bettega et al. 1998, Belli
et al. 2000), it becomes more difficult for in vivo tissues and endpoints, where often not
even the photon response parameters αx and βx are precisely known. Another approach to
obtain the tissue parameters is to fit them to simulations with other (e.g. track structure)
models, provided the tissue parameters for those models have already been determined (cf
the listing in Katz et al. 1994).
In summary, a phenomenological model for the RBE of protons as a function of the
dose, the dose averaged LET and tissue specific parameters was proposed. Although it
consists only of a few simple formulas, it reproduces the basic dependencies of RBE on
58
4.4 Discussion
dose and LET as observed by in vitro experiments. Despite being much simpler, our RBE
model was at least comparable to track structure models in the therapeutically relevant
LET region below 30 keV/µm.
The main advantage of the model is its ability to calculate three-dimensional RBE dis-
tributions extremely fast. All it needs are the tissue parameters and three-dimensional LET
calculations, which can be done as fast as common dose calculation algorithms (Wilkens
and Oelfke 2004). This makes it a useful tool to study the effects of a variable RBE even
in inverse treatment planning, which will be investigated in the following chapter.
On the other hand, the model has several limitations, and it is only a phenomenological
way to describe the RBE on the basis of experimental data. More experiments are required
to obtain the tissue parameters for more clinical tissue types and endpoints. However, if
one considers a constant RBE of 1.1 as the 0th order approximation of the RBE problem,
this model can certainly serve as a feasible approach for the derivation of first order effects.
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Chapter 5
New Optimization Strategies
5.1 Introduction
We can now take the methods for three-dimensional LET calculations and the phenomeno-
logical RBE model, which were developed in chapters 3 and 4, and apply them to the
treatment planning process in proton therapy. After calculating both dose and LET distri-
butions, the model for RBE as a function of dose, LET and tissue type allows us to obtain
RBE distributions for any given treatment situation. But rather than just executing a final
three-dimensional RBE calculation after the optimization of the physical dose, it would be
more interesting and useful to use the LET and RBE information during the optimization,
to come up with a treatment plan that is optimized in terms of the biological effect instead
of the physical dose. For this purpose, new optimization strategies are required that can
take these new issues into account.
The optimization is usually done by minimizing a so-called objective function using
iterative algorithms (cf section 2.3.2). We will see that we can use the same optimization
algorithm as before, although we have to change the objective function and add constraints
in terms of LET or the biological effect. These new objective functions and some details
on the implementation in KonRad are described in section 5.2.
In section 5.3, results for these new optimization strategies are presented. They are first
applied to spread-out Bragg peaks in water as a simple example to demonstrate the poten-
tial and the limitations of the new objective functions. After that, we will consider realistic
patient geometries given by computed tomography data sets, and scanning techniques for
intensity modulated proton therapy. Obviously, these studies can be of exemplary nature
only, although some general trends can be identified, which are discussed in section 5.4.
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5.2 Methods
In inverse treatment planning one usually aims for a homogeneous physical dose in the
planning target volume, leading to simple objective functions of the form
FD(w) =
∑
i∈PTV
(Di(w)−DPTV)2 , (5.1)
where the quadratic deviations between the actual dose Di in voxel i and the prescribed
dose DPTV are summed up for all voxels of the PTV. In practice, this objective function is
often modified to account for minimum and maximum dose constraints in the target and for
maximum dose constraints in organs at risk, which are weighted by so-called penalty factors
(cf section 2.3.2 and equation (2.5)). In the following, I will describe how this objective
function can be modified to account for the LET (section 5.2.1) and (more promising) for
the biological effect (section 5.2.2).
5.2.1 Objective function for LET constraints
As the RBE depends on dose, LET and tissue type, one new optimization strategy could
be to aim not only for a homogeneous dose, but also for a homogeneous LET distribution
in the target, as this would yield a homogeneous biological effect (RBE× dose). The
corresponding objective function (which will be called “LET objective function” in the
following) would be
FD,L(w) = νDFD(w) + νLFL(w) (5.2)
with
FL(w) =
∑
i∈PTV
(
Li(w)− L(w)
)2
, (5.3)
where νD and νL are penalty factors, Li is the dose averaged LET at voxel i and L is the
mean LET in the PTV:
L(w) =
1
NPTV
∑
i∈PTV
Li(w), (5.4)
where NPTV is the number of voxels in the PTV.
Note that we did not prescribe a certain LET value to the target volume (as such a
constraint would be extremely difficult to meet in the optimization), but we rather minimize
the variance of the LET in the target. However, it is still difficult to satisfy the constraints
of homogeneous dose and LET at the same time. To use this LET objective function in
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a simple gradient optimization algorithm, the first partial derivatives of FL have to be
known. As
∂Di(w)
∂wk
=
∂
∂wk
∑
j
wjDij = Dik and (5.5)
∂Li(w)
∂wk
=
∂
∂wk
1
Di(w)
∑
j
wjLijDij =
Dik
Di(w)
(Lik − Li(w)), (5.6)
they are
∂FL(w)
∂wk
=
∑
i∈PTV
2 · (Li − L) ·
[
Dik
Di
(Lik − Li)− 1
NPTV
∑
j∈PTV
Djk
Dj
(Ljk − Lj)
]
. (5.7)
The advantage of this approach would be that there are only physical parameters (dose
and LET) involved in the objective function, i.e. no tissue dependent biological parameters
have to be determined. But even for homogeneous dose and LET in the PTV, one would
still need one global (biological) RBE value for the whole PTV.
Another option for LET based objective functions would be to include maximum LET
constraints in organs at risk, which could be done in close analogy to the commonly used
maximum dose constraints (cf equation (2.5)). Again, this might be very difficult to ac-
complish due to the physical properties of the proton depth dose curve, which shows very
high LET at low doses in the region behind the Bragg peak. There is probably no reason
to penalize high LET values in a voxel that is exposed to very low doses only.
5.2.2 Objective function for the biological effect
A second, more general approach is the direct optimization of the biological outcome
(i.e. the product of RBE and dose). This will provide more degrees of freedom than the
objective function in the previous section, as dose and LET may vary within the PTV,
as long as the biological effect is constant. Rather than explicitly integrating the RBE
formula (4.7) from chapter 4 in the objective function, we will use the biological effect
E = − lnS = αD+βD2 from the linear quadratic model, as this offers some practical and
computational advantages. To get a homogeneous biological effect in the PTV, we just
have to change the objective function to
FE(w) =
∑
i∈PTV
(Ei(w)− EPTV)2 . (5.8)
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By applying equations (4.4) and (4.6) for the dependencies of the proton response param-
eters αPTVp and β
PTV
p on LET for the tissue of the PTV, we get
FE(w) =
∑
i∈PTV
(
αPTVp (Li(w))Di(w) + β
PTV
p D
2
i (w)− EPTV
)2
=
∑
i∈PTV
(
(αPTV0 + λ
PTVLi(w))Di(w) + β
PTV
p D
2
i (w)− EPTV
)2
=
∑
i∈PTV
(
αPTV0 Di(w) + λ
PTVLi(w) + βPTVp D2i (w)− EPTV
)2
, (5.9)
where Li(w) = Li(w)Di(w) is the product of LET and dose (cf section 3.2.4.3). Minimizing
this objective function will lead to a homogeneous biological effect and therefore to a homo-
geneous distribution of the product of RBE and dose in the PTV. The “prescribed effect”
EPTV can be connected to the prescribed X-ray dose DPTV by EPTV = αxDPTV+ βxD
2
PTV.
In the following, this new objective function will be called “RBE objective function”. In
this context I will even speak of “RBE optimization”, although it is certainly not the RBE
itself that is optimized, but rather the biological effect or the product of RBE and dose.
In equation (5.9), both Di and Li depend on the beam weights w, but the Newton
gradient method for the optimization still works. For this algorithm, the partial derivatives
of FE(w) have to be calculated. As
∂Li(w)
∂wk
=
∂
∂wk
Li(w)Di(w) =
∂
∂wk
∑
j
LijDijwj = LikDik, (5.10)
we get
∂FE(w)
∂wk
=
∑
i∈PTV
2
(
αPTV0 Di(w) + λ
PTVLi(w) + βPTVp D2i (w)− EPTV
)
× (αPTV0 Dik + λPTVLikDik + 2βPTVp Di(w)Dik) . (5.11)
For the Newton gradient approach as it is implemented in KonRad (cf Nill 2001, p 12),
the second partial derivatives are also needed:
∂2FE(w)
∂w2k
=
∑
i∈PTV
[
4
(
αPTV0 Di(w) + λ
PTVLi(w) + βPTVp D2i (w)− EPTV
)
βPTVp D
2
ik
+2
(
αPTV0 Dik + λ
PTVLikDik + 2β
PTV
p Di(w)Dik
)2 ]
. (5.12)
Note that in equations (5.9), (5.11) and (5.12) the LET Li never appears “alone”, but
only in products with Di, i.e. as Li. The latter can be calculated easily as
∑
j LijDijwj
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(cf section 3.2.4.3), which simplifies the computational effort required for evaluating these
equations.
If a minimum and a maximum constraint for the PTV are given (DPTVmin and D
PTV
max ),
they can be converted to minimum and maximum effect levels by
EPTVmin = αxD
PTV
min + βxD
PTV
min
2
and EPTVmax = αxD
PTV
max + βxD
PTV
max
2
(5.13)
and the corresponding objective function (cf equation (2.5b)) will be
F˜E(w) = ν
PTV
min
∑
i∈PTV
[C+(E
PTV
min − Ei)]2 + νPTVmax
∑
i∈PTV
[C+(Ei − EPTVmax )]2. (5.14)
This objective function can be extended easily to include maximum effect constraints in
organs at risk in the usual way as given in equations (2.5a) – (2.5c). While the respective
penalty factors keep the same meaning, all constraints that were given as an X-ray or
photon dose have to be translated to constraints in terms of the biological effect using
E = αxD + βxD
2. The tissue parameters αx, βx, α0, λ and βp are then needed for every
organ under consideration.
5.2.3 Implementation in KonRad
The new objective functions were integrated into our research version of the inverse plan-
ning tool KonRad (cf section 2.3). However, at the current point the implementation of
the LET objective function in KonRad is still work in progress, and I will therefore con-
centrate on the RBE objective function in the following. The methods for calculating and
accessing the Lij matrix and for obtaining three-dimensional LET distributions in KonRad
were already described in section 3.2.4. Now some additional input data are required for
the RBE objective function, and I will also describe what kind of output data is produced
by KonRad.
5.2.3.1 Input data for KonRad
Besides the usual functionality of theKonRad system (cf Nill 2001), the user can now choose
between either the “normal” optimization of the physical dose, or the new optimization of
the biological effect, i.e. using objective function (5.9). In any case, the user can request a
final calculation of three-dimensional LET or RBE distributions after the optimization to
study the LET and RBE effects for the normal optimization of the physical dose as well.
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If RBE calculations or the optimization of the biological effect are chosen, it is further
necessary to provide the biological tissue parameters αx, βx, α0, λ and βp for each classified
tissue volume or organ (PTV, organs at risk, normal tissue). If more than one organ at
risk are given, the parameters have to be specified for every OAR separately. They are
read into KonRad from a patient-specific configuration file. Internally, KonRad assigns a
set of tissue parameters to every voxel within the patient, depending on the (unique) organ
classification of the respective voxel.
Another point that has to be noted is that RBE calculations have to be done for the
dose per fraction rather than the total dose (cf chapter 4). To take this into account, the
user has to specify the number of fractions. The constraints for the optimization are given
as usual in terms of the total dose and they are then internally converted to doses per
fraction by dividing them by the number of fractions.
When optimizing the physical dose, the constraints are interpreted as physical proton
doses. In the case of optimizing the biological effect, the constraints specified by the user
are considered to be physical photon doses, i.e. they are the same as one would use for a
photon optimization. They are then translated internally to constraints in terms of the
biological effect as described above.
5.2.3.2 Output data from KonRad
After the optimization, the results are written to files: besides the dose cube, three-
dimensional distributions of dose averaged LET, RBE, RBE× dose and the surviving
fraction can be exported as requested by the user. Additionally, a file providing statis-
tical information of these cubes is created. It states the minimum and maximum values
of the respective distributions and the normalization values. These cubes can be further
processed and visualized as desired, e.g. to obtain dose-volume-histograms (DVHs) or to
compare different plans.
5.3 Results
The new objective functions that were introduced in the last section can be used either in
KonRad or in any other optimization program, e.g. for spread-out Bragg peaks. As the
latter are a simple example for the demonstration of the new optimization strategies, I
will first show some results for SOBPs (section 5.3.1). After that, the effects of the new
objective functions for several clinical cases with IMPT plans in KonRad are presented in
section 5.3.2.
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Parameter Value Unit
αx 0.112 Gy
−1
βx 0.0298 Gy
−2
α0 0.1 Gy
−1
λ 0.02 µm keV−1 Gy−1
βp 0.0298 Gy
−2
Table 5.1: Tissue parameters used in all calculations of the biological effect in this work.
They are the values for the survival of V79 Chinese hamster cells in vitro as derived in
chapter 4.
For the calculation of the biological effect with the phenomenological RBE model, a
set of biological parameters for every tissue under consideration is required. However, it
is not the aim of this work to derive exact parameter sets for clinically relevant tissue
types. We rather want to investigate the effects of a variable RBE in IMPT in general, and
therefore just one set of parameters is used for all organs or tissue types in all following
RBE calculations. For simplicity, we will use the values derived in section 4.2.2 for V79
Chinese hamster cells relative to 60Co gamma-rays, which are summarized in table 5.1.
5.3.1 Optimization of spread-out Bragg peaks
Spread-out Bragg peaks were optimized using a simple gradient algorithm and the objec-
tive functions given in section 5.2. A predefined number of pristine peaks was placed in
equidistant steps along the intended modulation width of the SOBP.
5.3.1.1 LET optimization
Let us first investigate the LET objective function (5.2), which aims at a homogeneous dose
and a homogeneous LET simultaneously. The relative importance of these two objectives
is given by the penalty factors νD and νL. Figure 5.1 shows an example for SOBPs with
three different penalty settings (νD = 1; νL = 0), (0; 1) and (0.5; 0.5), corresponding to
“pure dose”, “pure LET” and equally weighted optimization of both. All SOBPs consist
of 15 peaks with an initial energy of 70 MeV (range 40 mm), which are modulated in range
to cover the depth interval 11–31 mm. This energy in conjunction with SOBPs is typically
used for the treatment of ocular tumours.
The configuration given in figure 5.1a is of course just the usual SOBP with a homoge-
neous dose in the SOBP plateau. But here the LET increases along the plateau, as it was
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Figure 5.1: Dose (——) and LET (· · · · · ·, right ordinate) distributions for spread-out
Bragg peaks that were optimized for three different penalty settings in the LET objective
function: (a) pure dose optimization (νD = 1; νL = 0), (b) pure LET optimization (0; 1)
and (c) equal weighting of both objectives (0.5; 0.5). The red vertical lines indicate the
positions and the relative weights of the constituent pristine peaks.
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Figure 5.2: Total dose (——) and LET (· · · · · ·, right ordinate) distributions for two
opposing beam ports with a maximum energy of 160 MeV. The weights of the pristine
peaks were optimized to yield homogeneous dose and LET distributions in the depth interval
11.5–17.5 cm, using νD = 0.5 and νL = 0.5. The dose contributions of the two fields are
given by the broken lines.
already pointed out in chapter 3. If one aims for a homogeneous LET only (figure 5.1b),
this can be achieved by a modified dose profile: the dose is now much lower in the distal
part of the SOBP to compensate the increase in LET. In figure 5.1c, both objectives
are weighted equally, which apparently does not lead to a good compromise. While the
LET is not much better than in figure 5.1a, the dose distribution is considerably worse.
However, these results show that the new objective function works in principle. The unac-
ceptable results of figure 5.1c are due to the physical properties in terms of dose and LET
of the pristine Bragg peaks - it is simply not possible to have homogeneous dose and LET
simultaneously in a SOBP.
To get flat distributions of both dose and LET, one needs more degrees of freedom
in the optimization. This can be accomplished for example by two opposing beams for
the treatment of deep seated tumours (figure 5.2). Now there are several possibilities for
obtaining a flat total dose, and among them is also a solution that gives a homogeneous
LET distribution in the region of interest. For two opposing beam directions, each with 15
pristine peaks with a maximum energy of 160 MeV, the total dose and LET distributions
were optimized using νD = 0.5 and νL = 0.5. While the two beam ports both deliver a
non-uniform dose, the total dose and LET showed good uniformity in the “target” region
(figure 5.2). This means that although the LET optimization did not work satisfactorily
69
5. New Optimization Strategies
a)
depth in water (mm)
0 10 20 30
d
o
s
e
 (
G
y)
, 
R
B
E
 x
 d
o
s
e
 (
C
G
E
)
0
1
2
3
4
b)
depth in water (mm)
0 10 20 30
c)
depth in water (mm)
0 10 20 30
s
u
rv
iv
a
l 
(%
)
40
50
60
70
80
90
100
d)
depth in water (mm)
0 10 20 30
Figure 5.3: Dose (——) and RBE× dose (– – –) distributions for spread-out Bragg peaks
that were optimized to yield a homogeneous dose (left) and a homogeneous biological effect
(right) for the survival of V79 cells in vitro relative to 60Co. The red vertical lines indicate
the positions and the relative weights of the constituent pristine peaks. The corresponding
cell survival levels are given in panels (c) and (d).
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for one beam direction, it might have applications for more than one beam port, e.g. in
IMPT with the 3D modulation technique. However, this approach will not be pursued any
further in this work.
5.3.1.2 Optimization of the biological effect
Next, I will give an example for an SOBP that was optimized with the RBE objective
function (5.9). Now dose and LET are allowed to vary within the modulation region,
as long as the biological effect (RBE× dose) is uniform in the desired depth interval.
Figure 5.3 illustrates a typical result for a SOBP with 15 pristine peaks and a maximum
energy of 70 MeV (same configuration as in figure 5.1). On the left hand side (figure 5.3a)
is again the usual optimization of the physical dose (with 2 Gy in the SOBP), while the
graph on the right hand side (figure 5.3b) corresponds to the new objective function. In
both cases, the biological effect in terms of RBE× dose is also given. While RBE× dose
did not show a uniform plateau for the dose optimization (cf section 4.3), it became flat
for the RBE objective function. This was accomplished by reducing the dose in the distal
part of the SOBP and thereby compensating for the increasing RBE. In figures 5.3c and
5.3d, the surviving fraction of V79 cells as a function of depth is given for both cases. For
the dose optimization, there is a distinctive dip to smaller survival levels at the distal edge
of the SOBP, while this effect almost vanished for the RBE objective function.
5.3.2 Optimization of IMPT
In this section, the effects of a variable RBE for several clinical examples with IMPT
scanning techniques will be investigated. However, it is not the aim of this work to present
the best clinical plan for these cases, but rather to demonstrate the RBE effects and
optimization strategies for scanning techniques using typical patient geometries.
In particular, two cases will be studied in detail: a patient with a clivus chordoma,
and a patient with a carcinoma of the prostate. The chordoma was chosen because its
concave shape and its close location to the brainstem make it very difficult to treat with
conventional photon radiotherapy. It is therefore an ideal candidate for more sophisticated
techniques like intensity modulated radiotherapy (IMRT) with photons or IMPT. Fur-
thermore, chordomas are a standard tumour site in clinical proton therapy (e.g. Debus
et al. 1997, Noe¨l et al. 2001). Proton therapy is also used for prostate carcinomas (e.g.
Rossi 1999), although many of these tumours are treated with different modalities as well.
Due to their high rate of incidence, prostate carcinomas are frequently studied, and many
people could benefit from therapeutical improvements.
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Figure 5.4: Left: Transversal CT slice through the isocentre for the patient with the
clivus chordoma. The planning target volume (PTV) and the brainstem as organ at risk
are indicated by the red and green lines, respectively. The five incident beam directions
are given by the yellow lines. Right: Three-dimensional view of the PTV (red) and the
brainstem (green) as seen from the patient’s back. The eyes, the optical nerves and the
chiasm are also outlined.
For every case I will first describe the geometry of the anatomy and the planning objec-
tives. After that, several treatment plans using different scanning techniques (distal edge
tracking and 3D modulation) and different objective functions (dose or RBE optimization)
will be presented. All plans were optimized in KonRad using five coplanar, equally spaced
beam ports. For all plans a final calculation of three-dimensional LET and RBE distribu-
tions was performed, so that they can be evaluated and compared in terms of dose, LET
and RBE× dose.
5.3.2.1 Clinical case 1: clivus chordoma
Anatomy and clinical objectives The anatomy of the patient with the clivus chor-
doma is shown in figure 5.4. The planning target volume is situated in the centre of the
patient’s head and wraps closely around the brainstem as the primary organ at risk. The
five coplanar, equally spaced beam directions are indicated in figure 5.4. The maximum
beam energy used was 200 MeV for the anterior-posterior beam, and 160 MeV for all
other beams. The lateral distance between beam spots was set to 6 mm. This led to a
72
5.3 Results
Organ Dmin νmin Dmax νmax
PTV 68 CGE 99 71.5 CGE 20
brainstem — — 0 CGE 6
normal tissue — — 70 CGE 3
Table 5.2: Optimization constraints (minimum dose, maximum dose and the respective
penalty factors, cf equation (2.5)) for the clivus chordoma case. While the maximum dose
constraint for the brainstem is rather tight to spare the brainstem as much as possible, the
constraints for the PTV allow for small inhomogeneities in the dose distribution.
total number of 690 beam spots for distal edge tracking and 10 066 beam spots for 3D
modulation.
The objectives of the planning process were to deliver a homogeneous dose of 70 CGE
in 35 fractions to the PTV (i.e. with a dose per fraction of 2 CGE), while sparing the
brainstem as much as possible. The dose constraints used for the optimization are listed
in table 5.2 and were taken from Nill (2001), where an extensive planning comparison
for this patient using intensity modulated photon, electron, proton and carbon beams was
presented. Besides the brainstem, the “normal tissue” consisting of all patient voxels except
the PTV and brainstem was considered as an organ at risk in the optimization. The eyes,
the optical nerves and the chiasm were far enough away from the PTV not to be included
as separate organs at risk.
Note that the constraints are given here in units of CGE, i.e. in terms of “photon dose”.
For the RBE optimization, these values can be used directly to calculate the “prescribed
effect” (cf section 5.2.2). To compare the new RBE optimization with treatment plans ob-
tained by the usual optimization of the physical dose, the constraints have to be converted
to appropriate proton doses. This was done by dividing the constraints from table 5.2
by the mean RBE in the PTV, which was 1.14 for distal edge tracking and 1.25 for the
3D modulation (see below). This procedure ensured that the final (dose dependent) RBE
calculation after the dose optimization was done with the correct values for the proton
dose per fraction to yield the desired CGE level.
Treatment plans for distal edge tracking Let us first consider treatment plans using
the distal edge tracking technique. For the optimization constraints given above, two plans
were generated: the first plan was optimized using the “normal” objective function, i.e.
aiming for a homogeneous physical dose in the planning target volume. Dose and LET
distributions for this plan were already displayed in figure 3.10. Applying the RBE model
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Figure 5.5: Dose (left) and LET (right) distributions in a transversal slice through the
isocentre for the new RBE optimization using the distal edge tracking technique. The colour
scales are normalized to 100% = 1.75 Gy per fraction and 100% = 5 keV/µm, respectively.
in a final step after the optimization yielded the distribution of RBE× dose shown on the
left side of figure 5.6. For the second plan, the new RBE objective function was employed
to obtain a homogeneous biological effect. The corresponding distributions of dose, LET
and RBE× dose are given in figure 5.5 and on the right hand side of figure 5.6.
As expected, the dose optimized plan gave a uniform physical dose distribution that
was highly conformal to the PTV (left side in figure 3.10). However, as already seen in
chapter 3, the LET values were low in the centre of the PTV and much higher at the
border and outside of the PTV. This led to an inhomogeneous distribution of the RBE
and therefore also of RBE× dose, which becomes apparent in figure 5.6 (left hand side).
In particular, there are some regions of considerable overdosage, e.g. at the left and right
lateral edges of the PTV in the slice shown in figure 5.6 where RBE× dose exceeds 130%
(white isodose line) of the desired 2 CGE. Note that the highest LET values in the normal
tissue (e.g. in the region posterior of the PTV) do not have a significant impact on the
biological effect, since the dose is very low in this region due to the steep physical dose
gradient. This means that although the RBE is high, the product of RBE and dose is
still low. For this plan, the RBE in the PTV ranged between 1.0 and 1.6 with a mean
of 1.14, which is in agreement with the underlying cell survival experiments. The overall
RBE maximum in this plan was 2.8 in the normal tissue surrounding the PTV.
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Figure 5.6: Distributions of the product of RBE and dose in a transversal slice through
the isocentre for the normal dose optimization (left) and for the new RBE optimization
(right), both for the distal edge tracking technique. The colour scales are normalized to
100% = 2 CGE per fraction.
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Figure 5.7: Dose-volume-histograms for the two distal edge tracking plans for the clivus
chordoma. The DVHs of the PTV (red) and the brainstem (green) are given for the physical
dose (a) and for the product of RBE and dose (b). The solid lines correspond to the dose
optimization (optimized to yield 1.75 Gy per fraction), while the dotted lines show the DVHs
for the RBE optimization (optimized to 2 CGE per fraction).
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Statistical analysis for the PTV Min Max Mean σ
DET dose (Gy) 0.63 2.30 1.78 0.14
dose optimized LET (keV/µm) 1.0 7.3 2.1 1.1
RBE× dose (CGE) 0.73 2.97 2.02 0.23
DET dose (Gy) 0.40 2.17 1.78 0.17
RBE optimized LET (keV/µm) 1.0 8.3 2.1 1.1
RBE× dose (CGE) 0.55 2.77 2.01 0.15
3D dose (Gy) 0.53 2.07 1.61 0.11
dose optimized LET (keV/µm) 1.4 5.1 3.5 0.4
RBE× dose (CGE) 0.84 2.58 2.03 0.14
3D dose (Gy) 0.53 1.92 1.58 0.10
RBE optimized LET (keV/µm) 1.7 5.3 3.6 0.4
RBE× dose (CGE) 0.77 2.47 2.00 0.11
Table 5.3: Statistical analysis of dose, LET and RBE× dose distributions per fraction in
the PTV for four different treatment plans for the clivus chordoma: for both the distal edge
tracking technique and the 3D modulation, plans were considered using either the normal
dose optimization (“dose optimized”) or the optimization of the biological effect (“RBE
optimized”). For every case, the minimum and maximum values as well as the mean and
the standard deviation are given.
Let us now look at the RBE optimized plan (figure 5.5 and right hand side in figure 5.6),
which was optimized to yield a homogeneous biological effect in the PTV. Indeed, the prod-
uct of the variable RBE and the dose was now more homogeneous in the PTV (figure 5.6),
while the brainstem was mostly spared from dose. As the LET did not change much (cf
figures 3.10 and 5.5), this improvement in RBE× dose was achieved by varying the physi-
cal dose in the PTV: the dose is higher in the middle of the PTV, where the LET is low,
while the dose is lowered in the high LET regions at the PTV border, where the RBE
gets higher. While this effect is difficult to see in the “colourwash” displays of figures 3.10
and 5.5, it will become apparent for the prostate case in section 5.3.2.2, where profiles
through the dose distributions will be presented. These observations are also evident in
the dose-volume-histograms (figure 5.7): the DVH of the PTV for RBE× dose is steeper
for the RBE optimization than for the dose optimization, but the physical dose is less
homogeneous. A detailed comparison of the two plans is also given in table 5.3, where
minimum and maximum values as well as the mean and the standard deviation are listed
for physical dose, LET and RBE× dose.
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Figure 5.8: Distributions of dose (left) and LET (right) in a transversal slice through the
isocentre for the new RBE optimization using the 3D modulation technique. The colour
scales are normalized to 100% = 1.6 Gy per fraction and 100% = 5 keV/µm, respectively.
Treatment plans for 3D modulation I will now present treatment plans for the same
patient but with the 3D modulation technique instead of distal edge tracking. Again, one
plan was done with the normal dose optimization, and a second plan was obtained using
the RBE objective function. Dose and LET distributions for the normal optimization were
already displayed in figure 3.11. The corresponding distributions for the RBE optimiza-
tion are shown in figure 5.8, and the resulting distributions of RBE× dose are shown in
figure 5.9.
As we already saw in chapter 3, the 3D modulation technique shows a much more
homogeneous LET distribution in the PTV than the distal edge tracking technique. This
means that there are not much RBE variations in the PTV, and RBE× dose is more or
less uniform, even for the normal optimization of the physical dose (left side in figure 5.9).
Here the RBE in the PTV ranged between 1.1 and 1.6 with a mean of 1.25. If the RBE
optimization is activated, a slight improvement of the homogeneity of RBE× dose can also
be achieved in this case, although it is difficult to see in the colourwash displays (figure 5.9).
Only the DVHs reveal that RBE× dose in the PTV is better for the new optimization
method (figure 5.10). However, these differences are relatively small for the 3D modulation
technique. A numerical analysis of the respective dose, LET and RBE× dose distributions
can be found in table 5.3.
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Figure 5.9: Distributions of the product of RBE and dose in a transversal slice through the
isocentre for the normal dose optimization (left) and for the new RBE optimization (right),
both for the 3D modulation technique. The colour scales are normalized to 100% = 2 CGE
per fraction.
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Figure 5.10: Dose-volume-histograms for the two 3D modulation plans for the clivus
chordoma. The DVHs of the PTV (red) and the brainstem (green) are given for the physical
dose (a) and for the product of RBE and dose (b). The solid lines correspond to the dose
optimization (optimized to yield 1.6 Gy per fraction), while the dotted lines show the DVHs
for the RBE optimization (optimized to 2 CGE per fraction).
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Figure 5.11: Left: Transversal CT slice through the isocentre for the patient with the
prostate carcinoma. The planning target volume (PTV) and the rectum are given by the
red and yellow lines, while the bladder and the heads of the femoral bones are outlined in
blue and violet, respectively. The five incident beam directions are given by the yellow lines.
Right: Three-dimensional view of the PTV (red) and the surrounding organs at risk.
Organ Dmin νmin Dmax νmax
PTV 66 CGE 40 66 CGE 10
rectum — — 45 CGE 4
bladder — — 45 CGE 4
femoral heads — — 30 CGE 2
normal tissue — — 35 CGE 3
Table 5.4: Optimization constraints (minimum dose, maximum dose and the respective
penalty factors, cf equation (2.5)) for the prostate carcinoma case.
5.3.2.2 Clinical case 2: prostate carcinoma
Anatomy and clinical objectives As a second example, I will present a patient with a
carcinoma of the prostate. The anatomy of this case is shown in figure 5.11. The planning
target volume (PTV) is situated in the pelvis and is closely surrounded by rectum and
bladder as the most important organs at risk. The heads of the femoral bones are also
outlined as organs at risk. Again, five coplanar equally spaced beam directions were chosen
as indicated in figure 5.11. Here the beam energies ranged from 160 MeV up to 250 MeV.
Using a lateral distance of 5 mm between the individual beam spots led to a total of 1183
beams spots for the DET technique.
The objectives of the planning process were to deliver a homogeneous dose of 66 CGE in
35 fractions to the PTV (i.e. with a dose per fraction of 1.9 CGE, which is a reasonable value
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Figure 5.12: Dose (left) and LET (right) distributions in a transversal slice through the
isocentre for the new RBE optimization using the distal edge tracking technique. The colour
scales are normalized to 100% = 1.7 Gy per fraction and 100% = 5 keV/µm, respectively.
Profiles along the white horizontal line between the two femoral heads (left side) will be
shown in figure 5.15.
for prostate treatment, cf Rossi 1999). At the same time, the dose to rectum, bladder and
femoral heads as well as to the normal tissue had to be limited. In the case of overlapping
structures (e.g. PTV and rectum), priority was given to the PTV. The dose constraints
used for this case are listed in table 5.4. Again, the constraints are given in units of CGE,
i.e. in terms of “photon dose”, which can be directly used for the RBE optimization. For
the normal dose optimization, the constraints were converted to proton doses by dividing
them by the mean RBE in the PTV, which was in this case 1.11 for distal edge tracking
(see below).
As many RBE effects will be similar to those that we already saw for the clivus chordoma
case, I will shorten the presentation for the prostate case. In particular, I will show results
for the more interesting DET technique only. However, as an additional way of displaying
dose, LET and RBE× dose one-dimensional profiles through the three-dimensional cubes
will be given, as they are in this case very well suited to elucidate the differences between
normal and RBE optimization.
Treatment plans for distal edge tracking Two plans were generated for the opti-
mization constraints given above: one for the normal dose optimization, and a second one
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Figure 5.13: Distribution of RBE× dose in a transversal slice through the isocentre for
the new RBE optimization using the distal edge tracking technique. The colour scale is
normalized to 100% = 1.9 CGE per fraction.
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Figure 5.14: Dose-volume-histograms for the two distal edge tracking plans for the
prostate carcinoma. The DVHs of the PTV (red), bladder (blue) and the rectum (green)
are given for the physical dose (a) and for the product of RBE and dose (b). The solid
lines correspond to the dose optimization (optimized to yield 1.7 Gy per fraction), while the
dotted lines show the DVHs for the RBE optimization (optimized to 1.9 CGE per fraction).
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Statistical analysis for the PTV Min Max Mean σ
DET dose (Gy) 1.17 1.97 1.71 0.06
dose optimized LET (keV/µm) 0.9 4.8 1.8 0.8
RBE× dose (CGE) 1.42 2.39 1.90 0.13
DET dose (Gy) 1.01 1.97 1.71 0.12
RBE optimized LET (keV/µm) 0.9 5.3 1.8 0.8
RBE× dose (CGE) 1.31 2.26 1.90 0.07
Table 5.5: Statistical analysis of dose, LET and RBE× dose distributions per fraction
in the PTV for the two treatment plans for the prostate carcinoma. For every case, the
minimum and maximum values as well as the mean and the standard deviation are given.
for the RBE optimization. Two-dimensional distributions of dose, LET and RBE× dose
are given in figures 5.12 and 5.13 for the RBE optimization only. The respective distribu-
tions for the normal dose optimization look very similar on colourwash displays and are
therefore not shown separately. The differences between the two plans can be observed
better in dose-volume-histograms and in one-dimensional profiles (see below).
As already seen for the clivus chordoma case, the LET distribution for the DET tech-
nique shows low LET values in the middle of the PTV and higher LET values at the edges
and outside of the PTV (right hand side in figure 5.12). This behaviour does not change
much if one uses either normal or RBE optimization. The distribution of RBE× dose (fig-
ure 5.13) was homogeneous in the PTV and well shaped to its contour. The mean RBE in
the PTV was 1.11 in this case.
By comparing the dose optimized and the RBE optimized plans in dose-volume-histo-
grams (figure 5.14), it becomes apparent that RBE× dose in the PTV is more homogeneous
for the RBE optimization than for the dose optimization, as is was also observed in the
clivus chordoma case. The DVHs for RBE× dose of bladder and rectum are also slightly
better for the RBE optimization (figure 5.14b). On the other hand, the physical dose
distribution in the PTV becomes less uniform (figure 5.14a), because the RBE optimization
algorithm gives more dose in the middle of the PTV, where LET and RBE are low, and
less dose at the PTV edge, where LET and RBE increase. This can be clearly seen in
the dose profiles through the PTV given in figures 5.15a and 5.15c. It leads to a more
homogeneous profile of RBE× dose and survival as depicted in figures 5.15b and 5.15d.
A further comparison of the two plans can be found in table 5.5, where minimum and
maximum values as well as the mean and the standard deviation are given for physical
dose, LET and RBE× dose.
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Figure 5.15: One-dimensional profiles of dose (a), RBE× dose (b), LET (c) and the
surviving fraction (d) for the normal dose optimization (——) and the RBE optimization
(· · · · · ·). The profiles were measured along the white line indicated in figure 5.12; the
position of the PTV is marked by the dashed vertical lines. All values are given per fraction.
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Technique Objective function Optimization time
clivus chordoma prostate carcinoma
DET normal dose optimization 170 s 320 s
DET RBE optimization 370 s 870 s
3D normal dose optimization 930 s —
3D RBE optimization 2600 s —
Table 5.6: Optimization times for all treatment plans for the clivus chordoma case and
the prostate carcinoma case presented in the previous sections. The calculations were done
on a DEC Alpha workstation (500 MHz).
5.3.2.3 Calculation times
Table 5.6 gives the calculation times that were needed for the optimization of the treat-
ment plans given in the previous sections. All calculations were done on a DEC Alpha
workstation (500 MHz) and will be faster on modern GHz computers. These times are
for the pure optimization, i.e. excluding the time needed to create and fill the Dij and
Lij matrices. This took another 50 (940) seconds for the DET (3D modulation) plans for
the clivus chordoma, and 250 seconds for the prostate DET plans. Depending on the case
and the scanning technique, the RBE optimization therefore takes roughly a factor of 2–3
longer than the conventional dose optimization.
5.4 Discussion
In this chapter, new objective functions were developed that can account for LET and RBE
effects in the optimization process. They were applied to the optimization of SOBPs, and
to inverse planning for intensity modulated proton therapy with scanning techniques. The
proposed method for “RBE optimization” allows simultaneous multi-field optimization of
the biological effect, i.e. of the product of a variable RBE and dose in a reasonable time,
and is therefore well suited for studying the influence of a variable RBE in IMPT.
5.4.1 The effects of a variable RBE in SOBPs and IMPT
For the chosen tissue parameters (i.e. for cell survival in vitro), the RBE strongly depends
on the LET. The most important differences between dose and RBE× dose were therefore
found in regions that were exposed to a) high LET (leading to elevated RBE values) and at
the same time to b) high or at least intermediate doses (as otherwise the product of RBE
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and dose would still be low). These conditions can be found in the distal parts of SOBPs,
and for scanning techniques at the PTV border and in the region of the dose gradient
surrounding the PTV. To compensate for this effect, it is in most cases not possible to
change the LET distributions for a given irradiation technique, as the LET of a single
beam spot does not (unlike the dose) depend on its weight. It is therefore the physical
dose that has to be modified if a uniform biological effect is desired.
5.4.1.1 Optimization of spread-out Bragg peaks
While homogeneous dose and LET distributions simultaneously can be achieved for two
opposing SOBPs (figure 5.2), this is not possible for a single SOBP (cf figure 5.1). However,
the biological effect in a single SOBP can be made uniform by lowering the dose in the
distal part of the SOBP, as shown in figure 5.3. This effect has been known for a long
time (e.g. Blakely 1994, Paganetti and Schmitz 1996, Paganetti 1998), although in most
clinical applications it is only exploited for heavier charged particles (e.g. Chen et al. 1979,
Kanai et al. 1999, Schaffner et al. 2000, Kra¨mer and Scholz 2000). The RBE model and
the objective function presented in this work provide for an easy method to obtain these
isoeffective SOBPs for protons.
5.4.1.2 Optimization of IMPT
It was found that the effects of a variable RBE in IMPT depend on the type of scanning
technique used. As it was expected from the different LET distributions (cf chapter 3), the
impact of a variable RBE is much smaller for 3D modulation than for the DET technique.
The 3D modulation technique shows a more or less homogeneous LET within the PTV,
which leads to a relatively uniform RBE distribution. Applying the new RBE optimization
instead of the dose optimization can still improve the homogeneity of RBE× dose slightly
(figure 5.10). On the other hand, the LET distribution for DET is far less homogeneous in
the PTV. This leads to considerable RBE variations and to elevated levels of the biological
effect at the border of the PTV when using the normal dose optimization (cf figure 5.6).
The mean RBE in the PTV was smaller than for the 3D modulation, and the homogeneity
of RBE× dose was much worse than one would expect from the variations of the physical
dose using a constant RBE of 1.1. However, these unfavourable effects can be overcome
by the new RBE optimization, where the physical dose is modulated depending on the
local LET to yield a uniform biological effect and survival level across the PTV (as in
figure 5.15). Nevertheless, for the chordoma case the dose optimized 3D modulation plan
was still slightly better in RBE× dose than the RBE optimized DET plan (table 5.3).
85
5. New Optimization Strategies
For both scanning techniques, the differences between the two optimization methods
were mainly found in the PTV, whereas organs at risk were not much affected when switch-
ing from dose optimization to the RBE optimization. This can be understood qualitatively
because it is the PTV region where the optimization algorithm has most degrees of freedom
in increasing or decreasing the dose depending on the local LET. In organs at risk, one
would always want to keep the physical dose as low as possible anyway, and there is not
much room for the RBE optimization to reduce the dose further.
5.4.2 Limitations of the RBE optimization
Although the RBE variations observed in the previous sections qualitatively agree with the
current knowledge of radiobiology, the resulting RBE distributions have to be considered
with great care. In particular, they should not be interpreted as absolute RBE values
for the respective clinical case, but rather as a study of relative effects. This is mainly
due to the fact that tissue parameters for V79 cells in vitro were used instead of any
more relevant data sets for clinical tissue types in vivo. Thus the RBE values given in
this work almost certainly overestimate the real situation (cf section 4.4), at least in the
PTV. This might not hold for organs at risk, where non-lethal endpoints like mutations
or chromosome aberrations can be more important than survival. The problem how to
obtain better parameter sets was already discussed in section 4.4. A next step towards
more realistic situations could be to use three sets of tissue parameters, i.e. one for the
PTV, one for all organs at risk and one set for normal tissue. In that case, the distribution
of RBE× dose would not be “smooth” anymore, instead there would be discontinuities at
the boundary between different tissue types — and one would need to carefully address
the question what parameters to assign in “overlapping” regions.
One also has to keep in mind the other limitations of the models for LET and RBE
that were already discussed in section 3.4 and 4.4, in particular the dose range of the RBE
model. It probably does not hold for doses below 1 Gy, where hypersensitivity can occur
(Joiner et al. 2001, Schettino et al. 2001). However, the RBE optimization is not affected
by this as the dose per fraction in the PTV will in most cases be well above 1 Gy.
Furthermore, the dependency of RBE effects in IMPT on machine specific parameters
like the spot size or the energy spectrum of the beam spots was not investigated in this
chapter and leaves room for further research. With the methods given in chapter 3, it
will be very easy to obtain the required three-dimensional LET distributions for realistic
treatment situations in any particular proton facility under consideration.
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Chapter 6
Outlook on RBE for Heavy Charged
Particles
While the effects of a variable RBE are relatively small in proton beams, they become
essential in hadrontherapy with heavier particles, e.g. for carbon beams. For the latter,
clinical RBE values are of the order of 2–3 rather than 1.1, and neglecting their spatial
variation would lead to unacceptable results. Therefore the question arises whether the
methods presented in this work for protons can be applied to other ions as well, where the
clinical need for biologically optimized treatment plans is much higher.
Although light ions like helium, lithium or beryllium also promise therapeutical advan-
tages (e.g. Brahme 2004) and require careful RBE calculations (cf Tilly 2002), I will focus
on carbon beams, because they are clinically used at several centres. At the carbon ion fa-
cility of the Gesellschaft fu¨r Schwerionenforschung (GSI) in Darmstadt, three-dimensional
RBE distributions calculated with the local effect model (Scholz and Kraft 1994, Scholz
et al. 1997) are taken into account during treatment planning and optimization (Ja¨kel and
Kra¨mer 1998, Ja¨kel et al. 1999, Kra¨mer and Scholz 2000). However, besides requiring long
optimization times their system does not allow for real multi-field optimization. Instead,
every field has to be optimized individually, before they are added up in a final nonlinear
calculation step (Kra¨mer 2001). Somewhat easier methods of determining the RBE (e.g.
Kanai et al. 1997, 1999, Schaffner et al. 2000) are employed in Japan, where patients are
also treated with carbon beams.
If the algorithms for LET and RBE calculations (cf chapters 3 and 4) could be success-
fully transferred to heavier ions, the optimization strategies presented in chapter 5 would
offer a very fast method for simultaneous multi-field optimization of the biological effect
in heavy ion beams. In this chapter, I will therefore briefly describe how LET and RBE
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could be obtained for carbon ions, and I will illustrate in particular the problems that are
encountered and have to be solved in this approach.
6.1 LET calculations for carbon beams
As far as Coulomb interactions are concerned, the LET calculations can be transferred
easily from protons to carbon ions by appropriate scaling of the stopping powers. In first
approximation, the range Rion of an ion with atomic number Z and mass number A is A/Z
2
times the range of a proton of the same velocity, i.e. with the same energy per nucleon
(Raju 1980, p 195). Using the range energy relation Rproton = αE
p from equation (2.2),
we get
Rion(E) =
A
Z2
·Rproton(E/A) (2.2)= A
Z2
· α(E/A)p = A
1−p
Z2
·Rproton(E). (6.1)
This means the analytical expressions for dose (cf Bortfeld 1997) and LET (chapter 3)
can be used for other particles than protons if α is substituted by αA1−p/Z2, i.e. by
9.02×10−6 cm MeV−p for carbon ions (Z = 6, A = 12).
Using this modified α parameter and appropriate values for the width σE of the energy
spectrum (taking into account beammodifying devices like ripple filters, cf Weber and Kraft
1999), depth dose curves for pristine carbon Bragg peaks can be obtained which compare
well to experimental data in the entrance region as well as in the Bragg peak. However,
this model can obviously not describe the dose due to nuclear fragments originating in
nonelastic nuclear interactions and projectile fragmentation. As these secondaries can have
greater ranges than the primary carbon ions, they cause considerable dose values behind
the primary peak, the so-called “tail”. For any practical applications, this tail needs to be
modeled adequately.
The resulting distribution of the dose averaged linear energy transfer for carbon ions
looks qualitatively very similar to the proton LET curve (cf figure 2.1), although the
absolute values are approximately a factor of Z2 = 36 higher. For depths up to the Bragg
peak, these values agree reasonably well with the measured LET distribution for a carbon
beam given by Kanai et al. (1997). However, behind the peak the total LET over all
particles is (like the dose) dominated by the nuclear fragments. As the latter are lighter
than carbon, their stopping powers are smaller than those from the stopping primary
particles in the peak. Therefore the measured LET shows a steep falloff behind the Bragg
peak, which cannot be obtained by scaling the proton LET. This means that one either
has to include the fragments into the analytical LET model, or that the LET distributions
have to be taken from Monte Carlo simulations that account for hadronic interactions.
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Figure 6.1: Experimental results for the LQ parameters αC and βC as a function of
LET for the survival of V79 Chinese hamster cells in vitro under irradiation with carbon
ions (cf figure 4.1): (a) αC vs. LET, (b) βC vs. LET (• Kanai et al. 1997, ¤ Weyrather
et al. 1999). In (a), a linear fit according to equation (6.2) with αC,0 = 0.1 Gy
−1 and
λC = 0.004 µm keV
−1 Gy−1 was added, while the dotted line in (b) corresponds to a
constant βC of 0.0298 Gy
−2 .
In principle, the LET distributions could be precalculated with Monte Carlo techniques
for any desired beam energy, although the high number of possible beam energies for
synchrotron installations with active energy variation makes an analytical approach more
desirable.
Nevertheless, it certainly requires further investigation whether it makes sense to use
a dose averaged LET for different particle species, i.e. averaging the stopping powers of
primary carbon ions with secondary fragments like protons or alpha particles. For the
RBE calculations it might be necessary to keep separate LETs for every particle type, or
to use LET spectra instead of the dose averaged mean. Furthermore, the lateral behaviour
of the LET as described in section 3.2.2 for protons has to be studied for carbon ions as
well.
6.2 RBE modeling for carbon beams
To apply the phenomenological RBE model to carbon beams, experimental data for the
LQ parameters αC and βC as a function of LET are needed (cf chapter 4). Again, I will
concentrate on V79 cells, although there are also extensive data for human cell lines (e.g.
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Suzuki et al. 2000). From the data shown in figure 6.1, it seems that a linear function for
the dependence of αC on LET can be used for carbon as well, i.e.
αC(L) = αC,0 + λCL. (6.2)
The best fit parameters were αC,0 = 0.1 Gy
−1 and λC = 0.004 µm keV−1 Gy−1, while a
constant value for βC = βx = 0.0298 Gy
−2 can be assumed. Using these parameters and
αx = 0.112 Gy
−1 as in the previous chapters results in RBE values between 2 and 3 (at
2 Gy carbon dose) in the LET region found in SOBPs (∼75–150 keV/µm, Kanai et al.
1997), which are reasonable values for carbon ions.
An important issue that needs further clarification is the maximum LET value that
is relevant in therapeutical carbon beams, i.e. whether it is enough to model the linear
increasing part of the αC vs. LET relation, as it was the case for protons (cf section 4.2).
If, on the other hand, the decreasing part beyond the maximum becomes important, then
the argument from section 4.2.3 does no longer hold that α as a linear function of the dose
averaged LET is equivalent to the established model of a dose averaged α for mixed LET
irradiations (Zaider and Rossi 1980, Kanai et al. 1997).
The most critical point is certainly the influence of the nuclear fragments on the RBE,
which cannot be neglected. Therefore the relative contributions of all individual particle
species to dose and LET have to be known (fromMonte Carlo simulations or measurements,
cf Matsufuji et al. 2003), and their effect on RBE× dose needs to be investigated similarly to
a study by Paganetti (2002), where the influence of secondary particles in proton beams was
examined. This could help to identify the biologically most important particle types, which
subsequently have to be integrated into the LET calculations and the phenomenological
RBE model.
Nevertheless, this will require a concept to describe how the biological effects of different
particles add up nonlinearly in a mixed radiation field, and the total dose averaged LET
alone might not be sufficient for this approach, for example because the measured α(LET )
curves are in most cases particle specific. However, if a relatively simple model for the RBE
in carbon beams can be found, then the optimization strategies presented in chapter 5 will
offer a fast tool to study RBE effects in inverse planning for carbon ions.
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Summary and Conclusions
Before some final conclusions are drawn, I will briefly recapitulate the main parts of this
work. In order to study and to optimize the biological effects of a variable RBE in intensity
modulated proton therapy, fast models for three-dimensional LET and RBE calculations
were developed, and a new strategy was presented to utilize this information in inverse
therapy planning.
In chapter 3, a fast algorithm for three-dimensional calculations of the dose averaged
LET as a measure of the local radiation quality was derived, which offers the possibility
of obtaining LET distributions on computed tomography (CT) data sets for any desired
irradiation geometry (Wilkens and Oelfke 2004). It is based on an analytical expression
for the LET along the central axis of a single beam spot (Wilkens and Oelfke 2003) and
on the assumption of a laterally constant LET, which was motivated by Monte Carlo sim-
ulations. The algorithm was applied to clinical treatment plans and revealed considerable
differences in the LET distributions depending on the chosen scanning technique, even if
the dose distributions were very similar. Besides being used for RBE calculations, the
LET distributions might have applications in predicting the response of LET dependent
dosimetry systems (e.g. gel dosimetry or alanine detectors).
In a second step, a phenomenological model for the RBE in therapeutical proton beams
was developed in chapter 4. It describes the RBE as a function of dose, LET and tissue
specific parameters in the framework of the linear-quadratic model of radiobiology, and it
can reproduce the basic experimental results from cell survival measurements. The model
was applied to spread-out Bragg peaks (SOBPs), where the main effects of a variable RBE
are an increase of the RBE along the SOBP plateau and a shift in depth of the distal
falloff. The new method allows fast RBE estimations and is therefore well suited for the
purpose of this work, i.e. for the evaluation of RBE effects in inverse treatment planning.
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In chapter 5, new objective functions were presented that utilize the LET and RBE
information within the optimization loop of the inverse planning process. Instead of the
“normal” optimization of the physical dose, they allow the optimization of dose and LET, or
— most promising — the direct optimization of the biological effect in terms of RBE× dose
(“RBE optimization”). These new optimization strategies were applied to SOBPs as well as
to treatment plans for scanning techniques, where they provide a method for simultaneous
multi-field optimization of the biological effect in intensity modulated proton therapy. In
its current form, the RBE optimization takes approximately two to three times longer than
the conventional optimization of the physical dose, which makes it still feasible for practical
applications.
Finally, a brief outlook on the transferability of these concepts from protons to heavier
ions like carbon was given in chapter 6. For the latter, the consideration of a variable RBE
is essential for treatment planning, which makes a fast method for biological optimization
very desirable. However, this requires further investigation as the biological effects in such
beams are more complicated, mainly due to the fragmentation of the projectiles.
In short, the main conclusions can be summarized in four major points: (1) The LET
distributions for IMPT treatment plans can vary significantly depending on the chosen
scanning technique. (2) This influences the biological effect, which in certain situations
(e.g. for distal edge tracking) can become considerably worse than one would expect using
a constant RBE. (3) To evaluate these effects for a given treatment plan, the methods for
LET and RBE calculations presented in this work provide tools for fast identification of
potentially dangerous situations, e.g. regions of elevated or depleted LET. (4) Additionally,
unfavourable RBE effects can be compensated for by direct optimization of the product of
RBE and dose using new strategies that integrate the RBE into the optimization loop.
(1) LET variations The LET within a proton beam shows a steep increase at the end
of its range. This leads to significant differences of the LET distributions depending on
the scanning technique, although the corresponding dose distributions are very similar.
While the 3D modulation shows a more or less homogeneous LET within the planning
target volume (PTV), lower LET values are found in the centre of the PTV for distal edge
tracking. At the same time, the border of the PTV and the surrounding tissue are exposed
to much higher LET levels.
(2) Influence on the biological effect The LET variations lead to variations in the
biological effect, i.e. in the distribution of RBE× dose. The consequences of a variable
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RBE are therefore most important in the regions of elevated LET. This means that in
some situations — depending on the individual case and the scanning technique — the
deviations from a constant RBE can become potentially dangerous, for example at the
PTV border for the distal edge tracking technique or if Bragg peaks are placed very close
to critical structures. In other situations, however, the effects of a variable RBE are small,
and the use of a constant RBE is sufficient. Consequently, it is not possible to give a
general answer regarding the impact of RBE variations in proton therapy, as it depends on
the patient and the individual treatment plan. Nevertheless, if distal edge tracking shall
be employed, one should certainly be more concerned about RBE issues than for the 3D
modulation. The latter is definitely the safer option if no reliable RBE calculations are
available. In any case, the physical dose should not be the only criterion for comparing
treatment plans for different scanning techniques with protons.
(3) Evaluation tools To clarify the situation, tools were developed that allow the fast
evaluation of potential RBE effects for a treatment plan under consideration. First, three-
dimensional LET calculations can locate high and low LET regions, which are physical
properties of the radiation field. Secondly, if appropriate biological parameters are avail-
able, one can employ the phenomenological RBE model to compute a three-dimensional
distribution of RBE× dose to estimate the biological effects of the observed LET varia-
tions. Even if the tissue parameters are not precisely known, one can obtain qualitative
statements, e.g. where RBE effects are important, or simulate a worst case scenario.
(4) Optimization strategies If the evaluation of RBE effects reveals that a certain
treatment plan is not satisfactory from the biological point of view, one can either change
the setup for the plan, i.e. modify the beam directions or the scanning technique, or one can
employ the objective functions from chapter 5 to obtain an optimized distribution of the
biological effect. As the LET distribution for a given irradiation setup cannot be changed
extensively in most cases, the physical dose in the PTV must become inhomogeneous
in order to achieve a uniform biological outcome. The methods presented in this work
provide a feasible solution for such biological optimization, which can be implemented in
clinical practice as soon as reliable and appropriate tissue parameters have been derived.
Especially for DET, there seems to be a high potential in this approach, which can combine
the technical advantages of DET with an optimized distribution of the biological effect. On
the other hand, only slight improvements may be gained for the 3D modulation technique,
because its biological properties can be satisfying even for the normal optimization of the
physical dose.
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The points mentioned above include some implications for practical treatment planning.
If a variable RBE shall be used, the prescribed dose per fraction has to be known before
the RBE calculations or the RBE optimization are carried out, as the RBE model is based
on dose per fraction. Nonlinear effects prohibit a simple rescaling of RBE× dose to a new
prescription later on. Moreover, appropriate visualization tools are required to display the
distributions of LET, RBE or RBE× dose in addition to the physical dose. If two (or
more) different biological endpoints are of interest for the same organ at risk, one would
need even more than one distribution of RBE× dose for that region.
However, one has to keep in mind that the RBE model used in this work has several
limitations, and the accurate prediction of absolute RBE values for clinically relevant situ-
ations is very difficult. Since it is a phenomenological model, it cannot be better than the
experimental data that are used to derive its tissue parameters. Currently such data for
the relevant endpoints are scarce and there is certainly a clear need for more radiobiolog-
ical measurements in proton beams, especially for in vivo systems (Paganetti et al. 2002,
Paganetti 2003). Preferably, such studies should use realistic doses (1–3 Gy per fraction)
and explore several positions along the Bragg curve or the SOBP including the high LET
region at the distal edge in order to determine the LET dependence. Till then, data from
in vitro measurements as used in this work can be employed to estimate the potential
effects of a variable RBE, in particular the elevated RBE values in the distal part of the
Bragg curve. Independently of the tissue parameters, the calculation or even optimization
of three-dimensional LET distributions can help to identify and avoid unfavourable effects
in high LET regions.
In this work, radiobiological uncertainties of intensity modulated proton therapy were
investigated. It was shown that in some cases RBE effects can become potentially danger-
ous, which justifies the effort required to detect and compensate for these effects in order
to deliver the best possible treatment to the patient. Besides this radiobiological aspect,
there are still more challenges for IMPT. Among others, they include the development of
adaptive techniques that account for both intra- and interfraction organ motion, methods
for quantifying and minimizing adverse effects due to range uncertainties and last but not
least further advances in hardware components and quality assurance procedures. Nev-
ertheless, intensity modulated proton therapy — if carefully administered — carries high
potential for improved clinical results for tumour patients in radiotherapy.
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Appendix A
Derivation of the Analytical LET
Model
In this appendix, analytical expressions for LET distributions along the central axis of
proton beams in water are derived (cf section 3.2.1.1). The derivation follows closely the
work by Bortfeld (1997), in which an analytical approximation for the depth dose curve
was developed.
To work out the track averaged and dose averaged LET at depth z, we will need the
local proton spectrum ϕr(z) with respect to the residual range r and the stopping powers
SR(r) and S2R(r) (cf section 3.2.1.1). Expressions for these terms were already given in
equations (3.11), (3.16) and (3.17), respectively. They can now be used to evaluate the
three integrals (cf (3.8))
Φz =
∫ ∞
0
ϕr(z)dr, 〈S〉z =
∫ ∞
0
ϕr(z)SR(r)dr and 〈S2〉z =
∫ ∞
0
ϕr(z)S2R(r)dr. (A.1)
To solve these integrals we employ the parabolic cylinder functions Dν(x) (Gradshteyn and
Ryzhik 1994, Abramowitz and Stegun 1972). They obey the equation∫ ∞
0
r−ν−1e−(r−s)
2/2σ2dr = e−s
2/4σ2σ−νΓ(−ν)Dν(−s/σ) (ν < 0), (A.2)
where Γ(x) is the gamma function.
Let us first consider Φz. Inserting ϕr(z) from (3.11) yields
Φz =
∫ ∞
0
ϕr(z)dr =
Φ0√
2piσ
∫ ∞
0
e−(r−R0+z)
2/2σ2dr. (A.3)
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By using (A.2) and ζ := (z −R0)/σ we get
Φz =
Φ0√
2piσ
e−ζ
2/4σΓ(1)D−1(ζ) = Φ0√
2pi
e−ζ
2/4D−1(ζ), (A.4)
as Γ(1) = 1. For 〈S〉z, the stopping power from (3.16) is inserted into (A.1):
〈S〉z = Φ0√
2piσRα1/p
∫ ∞
0
e−(r−R0+z)
2/2σ2
[
(r +R)1/p − r1/p] dr (A.5)
=
Φ0√
2piσRα1/p
[ ∫ ∞
0
e−(r−R0+z)
2/2σ2(r +R)1/pdr −
∫ ∞
0
e−(r−R0+z)
2/2σ2r1/pdr
]
.
With (A.2), the second integral yields e−ζ
2/4σ1+1/pΓ(1+1/p)D−1−1/p(ζ). In the first integral
we can substitute u := r +R:∫ ∞
0
e−(r−R0+z)
2/2σ2(r +R)1/pdr =
∫ ∞
R
e−(u−R−R0+z)
2/2σ2u1/pdu
=
∫ ∞
0
f(u)du−
∫ R
0
f(u)du (A.6)
with f(u) = e−(u−R−R0+z)
2/2σ2u1/p. As R is small and f(u) is not divergent for u → 0, we
can approximate
∫ R
0
f(u)du by Rf( 1
2
R). With (A.2) and ξ := (z −R0 −R)/σ we get∫ ∞
0
e−(r−R0+z)
2/2σ2(r +R)1/pdr ≈
∫ ∞
0
f(u)du−Rf( 1
2
R)
= e−ξ
2/4σ1+1/pΓ(1 + 1
p
)D−1−1/p(ξ)−R( 12R)1/pe−(ζ+ξ)
2/8. (A.7)
Using D˜ν(ξ, ζ) = e−ξ2/4D−ν(ξ)− e−ζ2/4D−ν(ζ), we therefore obtain
〈S〉z ≈ Φ0√
2piσRα1/p
[
σ1+1/pΓ(1 + 1
p
)D˜1+1/p(ξ, ζ)−R( 12R)1/pe−(ζ+ξ)
2/8
]
(A.8)
To calculate 〈S2〉z, equations (3.17) and (3.11) are inserted into (A.1):
〈S2〉z = Φ0√
2piσRα2/pp(2− p)
∫ ∞
0
e−(r−R0+z)
2/2σ2
[
(r +R)2/p−1 − r2/p−1] dr. (A.9)
This expression can be evaluated in exactly the same way as (A.5) and leads to
〈S2〉z ≈ Φ0√
2piσRα2/pp(2− p)
[
σ2/pΓ( 2
p
)D˜2/p(ξ, ζ)− 2( 12R)2/pe−(ζ+ξ)
2/8
]
. (A.10)
The track averaged and dose averaged LET can now be calculated by simply inserting
equations (A.4), (A.8) and (A.10) into (3.9).
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